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1 Zusammenfassung 
Die Erstellung von Genexpressions-Profilen erlaubt profunde Einblicke in zellulärer 
Mechanismen unter physiologischen als auch pathologischen Bedingungen. Die 
Anwendung dieser Methode auf neurales Gewebe ist durch die enorme zelluläre 
Komplexität des Gehirns stark limitiert. Physiologisch relevante Veränderungen der 
Transkription in spezifischen Zellpopulationen können in komplexen Zellverbänden nicht 
detektiert werden. Daher ist die Aufreinigung einzelner Zelltypen aus Gewebsproben des 
zentralen Nervensystems (ZNS) somit ein hilfreicher Ansatz bei der Untersuchung des 
Expressionsprofils einzelner Zelltypen. Für die Umsetzung wurden in dieser Arbeit 
genetisch modifizierte Mausmodelle verwendet, die zelltyp-spezifisch Varianten des grün 
fluoreszierenden Proteins (GFP) exprimieren. Kombiniert mit speziellen 
Isolationstechniken, wie fluorescence activated cell sorting (FACS) oder laser capture 
microdissection (LCM), ist die Gewinnung intakter RNA aus unfixierten Zellen für die 
globale Transkriptionsanalyse einzelner Zelltypen möglich. In dieser Studie wurden FACS 
und LCM zur Isolation von definierte Neuronen und Gliazellen eingesetzt, um daraufhin 
Erkenntnisse über  zelltyp-spezifische Genexpression zu gewinnen. Mittels FACS wurden 
Expressionsprofile von glialen Vorläuferzellen, Mikroglia und Oligodendrozyten erstellt 
und eine Transkriptom-Datenbank für gliale Zelltypen generiert. Ferner wurde mittels 
LCM das Expressionsprofil einzelner Projektionsneurone aus dem Kortex von Cnp1 und 
Plp1 mutanten Mäusen von frühen Krankheits- bis hin zu massiven pathologischen 
Stadien untersucht. Diese Mausmutanten entwickeln im adulten Tier axonale 
Degenerationen, wie sie in vielen neuro-degenerativen Erkrankungen, zum Beispiel 
Parkinson, Alzheimer oder Multipler Sklerose, beschrieben werden. Die Identifikation der 
molekularen Mechanismen, die mit diesen axonalen Degenerationen einhergehen, ist 
notwendig für die Entwicklung therapeutischer Ansätze. Für die Charakterisierung der 
Expressionsprofile der degenerierenden Projektionsneurone in diesen Mausmutanten, 
wurden zu vier Zeitpunkten während des adultem Stadiums Gewebsproben isoliert und 
analysiert. Mit Hilfe dieser konnte eine „Momentaufnahme“ der Expressionsprofile von 
definierten neuronalen Subpopulation in vivo gemessen werden. Diese Studie liefert 
Auskunft über bekannte wie auch neue Kandidantengene und potentielle Mechanismen, 
die womöglich eine wichtige Rolle in der Verarbeitung und Kompensation von 
pathologischen Vorgängen neuro-degenerativer Erkrankungen spielen. 
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2 Summary 
Global gene expression profiling is a powerful tool to obtain deep insights into 
physiological and pathological cellular mechanisms. The enormous cellular complexity 
of the mammalian brain, however, is a major obstacle for gene expression profiling. 
Physiologically relevant changes of transcription that occur in specific cell populations 
are likely to remain undetected in cellularly complex samples. The purification of single 
populations of neural cell types eliminates these difficulties. We have approached this 
problem in transgenic mice by labelling genetically-defined neural cell types that 
express variants of GFP. When combined with isolation techniques such as 
fluorescence activated cell sorting (FACS) or laser capture microdissection (LCM), the 
isolation of intact RNA from unfixed cells for global transcriptome analysis is possible. 
In this study we applied FACS and LCM to isolate neurons and glia to gain insight into 
cell type specific gene expression. We profiled glial precursor cells, microglia and 
oligodendrocytes using FACS and generated a transcriptome database for glial cell 
types. LCM was used to study single isolated callosal projection neurons from the 
cortex of mouse models, which develop adult onset axonal degeneration a hallmark of 
many neurodegenerative diseases such as parkinson disease, Alzheimer disease and 
Multiple Sclerosis (MS). The identification of molecular mechanisms underlying axonal 
degeneration is critical to design rational therapies for neurodegenerative diseases. 
Therefore we profiled wild type controls, Cnp1 and Plp1 null mutant mice (myelin 
specific genes) at 4 different time points during adulthood. Cnp1 and Plp1 null mutants 
show axonal swellings and with age severe neurodegeneration, although CNS myelin 
seems ultra structural not affected. 
In summary, we have shown the feasibility to "snapshot" gene expression profiles of 
genetically defined neuronal subtypes in vivo and to compare morphologically similar 
neurons at a given time in pathological conditions. We followed gene expression 
changes starting from early disease states until stages of severe pathological signs, 
focusing on cells known to be susceptible to a genetic predisposition. Our analysis 
revealed several known and novel candidate genes and mechanisms that likely play a 
role in the early adaptive responses of cortical projection neurons to cope with axonal 
stress. 
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3.1 Cell type diversity in the brain 
The mammalian central nervous system (CNS) comprises a large number of 
local and regional circuits that are formed by precise connections between 
neurons, which themselves are quite diverse from the perspective of 
morphology, physiological activity, and expression of specific neurotransmitters. 
The realization that cortical cell types are highly diverse was first made by early 
anatomists using Golgi staining to reveal axonal and dendritic morphology (S 
Ramon y Cajal, 1952). But neuronal populations comprise a minority in the CNS 
of higher vertebrates - approximately 90% of the human brain consists of glial 
cells populations such as astrocytes, oligodendrocytes, and microglia (F. He and 
Sun, 2007). All these different cell types are highly interconnected (Fig. 1).  
 
Fig. 1: Main cell types in the CNS 
This diagram illustrates the relationships between the various CNS cell types. Depicted 
are connections formed between neurons, astrocytes, microglia, and myelinating 
oligodendrocytes as well as ependym cells and blood capillaries. 
Therefore the complexity of neural networks in the CNS is enormous, resulting 
not only from the vast possible combinations and variations of cell-cell 
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interactions, such as inter-neuronal, neuron - glia or glia - glia contacts, but 
also owing to the diverse functions that neurons and glia serve themselves. The 
molecular nature of neuron–glia interactions that control and underlie 
development, function, and pathology of the mammalian brain remains among 
the greatest unsolved mysteries in neurobiology today. 
3.1.1 History of neuroglia 
Rudolf Virchow described in 1846 for the first time the brain connective tissue 
what he called ‘nervenkit’ or neuroglia (Virchow, 1856), which in his eyes was 
set against the concept of nervous elements: 
‘Hitherto, gentlemen, in considering the nervous system, I have 
only spoken of the really nervous parts of it. But if we would 
study the nervous system in its real relations in the body, it is 
extremely important to have a knowledge of that substance also 
which lies between the proper nervous parts, holds them together 
and gives the whole its form in a greater or less degree’  
During the second half of the 19th century many different forms of glial cells 
were described for instance by Otto Deiters, Jacob Henle, Camillo Golgi, and 
Gustav Retzius (Deiters, 1865; Henle and Merkel, 1869; Golgi, 1874; Retzius, 
1894). In fact it was Camillo Golgi who described in 1871 a novel cell type in 
the CNS characterized by long, numerous, star-like processes (Golgi, 1874). In 
1893, Michael von Lenhossék called this characteristic cell type ‘astrocyte’ 
(Lenhossék, 1895). At that time the concept that non-neuronal cell types are 
highly diverse was already established within field experts. 25 years later, Pio 
del Rio-Hortega identified microglia and oligodendrocytes as separate cell types 
(del Rio-Hortega, 1919). But it took 30 years more until myelin was described 
to be part of the Schwann cell (Geren, 1954). Ramon y Cajal once raised the 
question (S. R Ramon y Cajal, 1911): 
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‘What is the function of glial cells in neural centers? The answer is 
still not known, and the problem is even more serious because it 
may remain unsolved for many years to come until physiologists 
find direct methods to attack it’  
Until now, this question is still not entirely answered. Several concepts have 
been developed which appoint multiple roles to glial cells in brain function. Here 
we summarize briefly the basic concepts of the three non-neuronal cell types, 
namely astrocytes, oligodendrocytes, and microglia. 
3.1.2 Astrocytes – function and physiological role 
Astrocytes derive from neuroepithelial cells that form the ventricular zone; 
these progenitors give rise to astrocytes, neurons, and oligodendrocytes 
(Horner and Palmer, 2003). The mammalian CNS astrocytes are highly 
abundant and represent approximately 1/3 of the cells in the human brain (F. 
He and Sun, 2007). In the course of vertebrate evolution, there is evidence of a 
relative expansion of astrocytes in comparison to neurons, implying an 
evolutionary advantage of animals with a greater number of astrocytes 
(Nedergaard et al., 2003). In mammals astrocytes can be distinguished into two 
types: the protoplasmic and the fibrous. Protoplasmic astrocytes are found in 
the grey matter, have shorter and thicker processes and are mainly associated 
with synapses. Fibrous astrocytes, on the other hand, have long and thin 
processes, contain many filaments, and are mainly localized in the white 
matter. Both types of cells share similar functions, although they are 
morphologically and structurally different. Astrocytes are in direct contact with 
blood capillaries and play an important role in the metabolic supply of the CNS. 
Another major astrocytic function is the support of neuronal function by 
maintaining local ion concentrations, storing CNS glycogen, clearing neuronal 
waste, supplying neurotrophic factors and mediating the uptake of 
neurotransmitters (A. Nair et al., 2008) and (Dreyfus et al., 1999). However, 
another interesting role of astrocytes is their involvement in the CNS immune 
responses. Although their origin is not linked to the hematopoietic cells, they 
exhibit immune functions. They express toll-like receptors, act as antigen-
INTRODUCTION 
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presenting cells and produce a variety of cytokines and chemokines. Astrocytes 
are also important for the signaling to the periphery as they secrete chemokines 
and cytokines and their end-feet contact the blood vessels (Dong and 
Benveniste, 2001). Activated astrocytes up-regulate their expression of GFAP in 
a process termed “astrogliosis”, a term that has commonly been used as a 
marker for pathology in CNS diseases. The role of astrocytes in pathology can 
be dual. In multiple sclerosis (MS), astrocytes are responsible for the 
breakdown of the blood-brain barrier, the recruitment of T cells, along with the 
axonal damage and the oligodendrocytic death through the secretion of 
cytokines. On the other hand, astrocytes promote remyelination by helping to 
clear debris, secreting chemo-attractants for oligodendrocyte precursor cells 
(OPCs) and supporting the OPC survival, proliferation, and maturation (A. 
Williams et al., 2007). Astrocytes have both a beneficial and a detrimental role 
in the CNS after injury. They form a glial scar, which is thought to protect the 
fragile brain tissue from further destruction (Myer et al., 2006). On the other 
hand, the formation of a mechanically obstructive glial scar composed of 
astrocytes and connective tissue elements is partially responsible for the failure 
of neuronal regeneration within the CNS after injury (Fitch and Silver, 2008). 
3.1.3 Oligodendrocytes – function and physiological role 
Oligodendrocytes (from Greek, literally meaning cells with a few branches), or 
oligodendroglia (Greek, few tree glue), comprise a variety of neuroglia whose 
main function is the insulation of axons exclusively in the CNS of higher 
vertebrates (the same function is performed by Schwann cells in the peripheral 
nervous system). A single oligodendrocyte can extend its processes to 50 
axons, wrapping approximately 1 mm of myelin sheath around each axon; 
Schwann cells can only wrap around 1 axon. 
Oligodendroglia arises during development from OPCs, which can be identified 
by their expression of a number of antigens, including the ganglioside GD3 
(Curtis et al., 1988; LeVine and J.E. Goldman, 1988; Hardy and Reynolds, 1991; 
Levine et al., 1993), the NG2 chondroitin sulfate proteoglycan (Levine et al., 
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1993), and the platelet-derived growth factor receptor, alpha polypeptide 
(PDGFRA) (Pringle et al., 1992). In the mouse forebrain, the majority of 
oligodendroglial progenitors arises during late embryogenesis and early 
postnatal development from cells of the subventricular zones (SVZ) of the 
lateral ventricles. SVZ cells migrate away from germinal zones to populate both 
developing white and gray matter, where they differentiate and mature into 
myelin-forming oligodendroglia (Hardy and Reynolds, 1991; Levison and J.E. 
Goldman, 1993). However, it is not clear whether all oligodendroglial 
progenitors undergo this sequence of events. It has been suggested that some 
undergo apoptosis (B A Barres et al., 1992) and others fail to differentiate into 
mature oligodendroglia but persist as adult oligodendroglial progenitors (Wren 
et al., 1992). 
As part of the nervous system, oligodendrocytes are closely related to nerve 
cells and, like all other glial cells, oligodendrocytes provide a supporting role for 
neurons which are introduced in more detail in section 3.2.1. 
3.1.4 Microglia– function and physiological role 
Microglial cells are considered as the immune cells of the CNS (Perry and S. 
Gordon, 1988; G W Kreutzberg, 1996). The origin of this cell type is not entirely 
clear to date. The current concept is that during embryonic development 
mesodermal glial cells invade the CNS parenchyma, followed by the second 
entrance of bone marrow-derived monocytes during the postnatal period (Rock 
et al., 2004; W.Y. Chan et al., 2007). Based on their morphology and status, 
microglia can be classified into two groups: the “resting” and the “activated” 
microglia. The “resting” microglia have a ramified morphology with many thin 
processes extending from the cell soma, while the “activated” ones have a 
round, amoeboid morphology. Activation of microglia is associated with cell 
transformation to phagocytes, capable of releasing potentially cytotoxic 
substances such as oxygen radicals, proteases, and proinflammatory cytokines 
(Colton and Gilbert, 1987; Banati et al., 1993). Recent studies have indicated 
that activation of microglia precedes or is concomitant with neuronal and glial 
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cell degeneration in neurologic disorders including Alzheimer's disease (P. L 
McGeer and E. G McGeer, 1995), Parkinson's disease (P L McGeer et al., 1993), 
multiple sclerosis (B\ö et al., 1994), and acquired immune deficiency syndrome 
dementia complex (Dickson et al., 1991; Gelman, 1993). The amoeboid phase 
is evident in early development during plasticity, while later on in adulthood 
microglia are in the “resting” mode. Under any kind of pathology, the microglia 
react and become “activated”, not only by changing their morphology but also 
their metabolism, so that they can cope with the homeostatic changes (van 
Rossum and Uwe-Karsten Hanisch, 2004). The distinction of the microglial 
morphologies and the activating signals is highly complicated, as described in 
more detail in multiple excellent reviews (Streit et al., 1988; Barron, 1995; J. 
Gehrmann et al., 1995; Gonzalez-Scarano and Baltuch, 1999; Suzumura et al., 
1991; U. K Hanisch and H. Kettenmann, 2007). 
So far it is known that microglial activation is crucial for the involvement of the 
adaptive immune system, as microglia are the key components for the 
recruitment of neutrophils, leukocytes and macrophages (Aloisi, 2001). 
Nevertheless, microglial activation is a double-edged sword, as it is generally 
beneficial and acts in a protective way. But chronic microglial activation leads to 
neuronal damage and accounts for the injury observed in certain 
neurodegenerative diseases, such as Parkinson’s disease and MS (Gao and 
Hong, 2008; Lassmann, 2008). The “resting” microglia were previously 
regarded as dormant cells. However, recent in vivo two-photon microscopy of 
transgenic mice expressing EGFP under the Cx3cr1 promoter revealed that 
“resting” microglia have highly motile processes that roam the intercellular 
space, extending and retracting in a very dynamic fashion (Nimmerjahn et al., 
2005; Davalos et al., 2005). Their somata remain stationary, while their 
processes constantly retract and rebuild, enabling the microglial surveillance of 
the brain parenchyma without perturbing the already existing glial-neuronal 
structures. Nonetheless, so far little is known about what controls and restricts 
this microglial activity in the healthy CNS.  
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3.1.5 Transcriptional profiling of specific CNS cell types 
Given the advances in transcriptome analysis in the recent years, genome-wide 
gene expression profiling could provide a sound and unbiased method for 
neural cell type classification (Markram et al., 2004; Mott and Dingledine, 
2003). This approach relies on the assumption that the overall function of a 
specific cell type within its context is highly correlated with its gene expression 
profile. DNA microarrays provide an ideal platform for such studies. To date, 
however, microarrays have not been effectively and systematically employed to 
address problems in cell type characterization. In the CNS, the majority of 
microarray experiments have been carried out on tissue homogenates, not 
allowing a precise distinction between cell types (Mirnics et al., 2000; Sandberg 
et al., 2000; Xinyu Zhao et al., 2001a; Zirlinger and D. Anderson, 2003). 
There are two experimental problems that, if solved, would greatly accelerate 
progress in further characterization of cell types within the mammalian brain: 
First of all, the rapid and unambiguous identification of distinct cell types in the 
CNS without compromising RNA integrity; secondly, the isolation of the distinct 
cell types from the CNS in order to subject them to further analysis on their 
transcript or protein level while at the same time preserving RNA and / or 
protein integrity. 
Over the last decade the number of available tools and methods to address 
these problems have radically advanced. Defining and identifying cell types was 
greatly improved by the availability of specific antibodies, but more importantly 
by genetic tools (Nolte et al., 2001; Jung et al., 2000; P.G. Hirrlinger et al., 
2005; Rossner et al., 2006). Now cells can be distinguished for instance by 
known markers using immunocytochemical labeling, or by stereotaxic injection 
of fluorescent tracers into projection targets. Defined cell types or even 
subpopulations can be identified using fluorescent proteins, which expression 
are controlled by specific promoters or enhancers. Several studies have been 
carried out employing such labeling techniques (Z. Yang et al., 2005; 
Buchstaller et al., 2004; Colosimo et al., 2004; Rossner et al., 2006) to gain 
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insight into the genome-wide transcriptional profiles of specifically labeled cell 
types.  
Data derived from DNA microarray studies in conjunction with several cell 
isolation techniques have lead to a better understanding of the generation and 
function of defined cell types in the CNS. The use of immunocytochemical 
labeling, isolation, and manual sorting of neuronal cells has lead to the 
identification of cell type-specific gene expression patterns for 12 different 
neuronal subtypes and the generation of a detailed taxonomic tree (Sugino et 
al., 2006). A different experimental approach characterized the specification 
and development of retrogradely labeled cortical projection neurons using 
fluorescence activated cell sorting (FACS) (Arlotta et al., 2005). In addition, 
striatal projection neuron subtypes were profiled with FACS (Lobo et al., 2006). 
Moreover, purified rat OPCs and premyelinating, postmitotic oligodendrocytes 
(OLs) have been profiled to reveal developmental gene expression changes 
during OL specification and differentiation (Nielsen et al., 2006; Dugas et al., 
2006). A global and direct comparison between two major CNS neural cell types 
such as astrocytes and myelinating OLs has also been undertaken by Cahoy 
and colleagues (Cahoy et al., 2008). All approaches mentioned thus far are 
restricted to late embryonal or early postnatal development owing to the 
inability of the employed techniques to isolate the mentioned cell types due to 
their high fragility at later time points. 
3.1.6 Laser capture microdissection; a tool for precise single cell 
isolation 
Laser capture microdissection (LCM) allows precise separation of both single 
cells and small cell groups from a variety of tissues under direct microscopic 
observation. One of the major advantages of LCM is the fact that it can be 
combined with a variety of additional methodologies to further the isolation of 
distinct cells or groups of cells. LCM has been used in combination with tracers, 
reporter gene expression, with histological staining methods and with 
transgenically labeled cell types through the expression of fluorescent proteins. 
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However, the limiting factor of this approach is obtaining consistently high 
quality RNA from small amounts of starting material. 
So far neurons have been a favored target for such investigations, both 
because of their clinical importance in neurodegenerative disorders such as 
Parkinson's disease and because they are readily labeled by antibodies to 
tyrosine hydroxylase (TH), the enzyme responsible of dopamine production. 
Two groups (Chung et al., 2005; Greene et al., 2005) compared dopaminergic 
neurons from neighboring midbrain regions, the ventral tegmental area (VTA) 
and the substantia nigra (SN), to identify genes contributing to the higher 
susceptibility of SN neurons to neurodegeneration in Parkinson’s disease. All of 
these studies used antibody labeling or retrograde tracers to identify distinct 
cell populations. Drawbacks of these techniques are for example additional 
factors such as prolonged treatment in aqueous phase in the case of antibody 
labeling, which increases RNA degradation processes, or retrograde labeling 
interfering with the system under investigation. The use of cell type-specific 
transgenes allows the labeling of identical cells or cell populations with virtually 
no variance within a given mouse strain, thus increasing reproducibility of 
experimental data (Rossner et al., 2006). However, the choice of the proper 
reporter is crucial for successful labeling and subsequent LCM to achieve 
specificity. In a previous study we could demonstrate that the fluorescent signal 
of ‘conventional’ reporter mice harboring a Thy1-EYFP transgene construct, is 
lost during preparation, most likely because of rapid diffusion (Fig. 2). We 
could further show that nuclear targeting of enhanced yellow fluorescent 
protein (EYFPnuc) is sufficient to retain a strong and unambiguous signal after 
section preparation. In our generated mouse line, EYFPnuc expression is placed 
under transcriptional control of the Thy1 promoter and labels predominantly 
cortical layer V callosal projection neurons (CPN) (Caroni, 1997).  
The generated reporter mouse is thus suitable to transcriptionally profile a 
specific subpopulation of cortical neurons during development and aging. 
Furthermore, this tool could provide insight into transcriptional changes that 
occur during encephalopathies like MS.  
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Fig. 2: Conventional GFP derivatives are not compatible with laser-directed micro-
dissection. The cellular signal of a nuclear-targeted EYFP (EYFPnuc) is preserved 
in freeze-dried cryosections obtained from transgenic mice. 
(A-C) The cellular resolution of EYFP expressed in transgenic mice is lost after 
cryosectioning. Sagittal sections of mouse brains from mice expressing cytoplasmic 
localized EYFP under the control of the Thy-1 promoter were either fixed with 4% 
buffered PFA or immediately frozen on dry ice. (A, A’) Vibratome sections obtained 
from PFA fixed tissue (30 µm) and (B, B’) cryosections (15 µm; Cryo) from frozen 
tissue, were analyzed for EYFP fluorescence. After cryosectioning, the cellular resolution 
of the EYFP fluorescent signal is lost. The EYFP signal is retained but appears to be 
diffuse and faded. (C, C’) Staining of the cryosection with thionin (Cryo) reveals that the 
cellular integrity of the tissue specimen is intact. (D-D’’) Nuclear targeted fluorescent 
proteins appear to be promising candidates for a combined in vivo labeling and 
microdissection approach. In the hippocampus, EYFPnuc+ nuclei can be detected in the 
granular cell layer (DG) and in the CA1 field of the pyramidal cell layer (CA1). In the 
CA3 field (CA3), fewer cells are EYFP positive. (D’) Higher magnification of EYFP+ 
nuclei in the somatosensory cortex. Scale bar, 50 µm. (D’’) In the cortex, cells located in 
deeper layers show a nuclear EYFPnuc signal. The inset shows the morphology of the 
section at the level of the somatosensory cortex in bright field. Adapted from (Rossner et 
al., 2006) 
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3.2 Neuronal gene expression profiles of myelin mutant 
mice 
So far only a few groups (Lu et al., 2004; Bernard et al., 2009; Chung et al., 
2005) applied cell isolation techniques like LCM in combination with high 
throughput transcriptional profiling to investigate pathological changes in a 
specific cell population, which are mediated by dysfunction of a different but 
phenotypically unaffected cell type. Unraveling the transcriptional changes in 
these cells may help to identify disease-relevant mechanisms or transcriptional 
hallmarks. Once disease-relevant genes have been identified, treatments which 
more specifically interfere with the disease-causing mechanism could be 
developed. Established mouse models in which neurodegeneration (caused by 
axonal loss) is triggered by a dysfunction of oligodendrocytes are the Cnp1 null 
as well as Plp1 null mutants (Klugmann et al., 1997; Lappe-Siefke et al., 2003).  
3.2.1 Mouse models of neurodegeneration 
3.2.1.1 Cnp1 null mice – a  model of ‘primary’ axonal pathology 
2’, 3’-cyclic nucleotide 3’-phosphodiesterase (CNP) constitutes 4-5% of the total 
CNS myelin protein content and is expressed as the first of the major myelin-
related proteins during brain development (Sprinkle et al., 1978). Cnp1 
expression is a marker of myelinating oligodendrocytes from early pre-
myelinating stages till adulthood (P E Braun et al., 1988). In oligodendrocytes 
and their progenitors, Cnp1 localizes to the cytoplasm (Nishizawa et al., 1985) 
or cytoplasm-containing uncompacted myelin regions such as the inner/outer 
mesaxon and paranodal loops (Kurihara and Tsukada, 1967; P E Braun et al., 
1988). Outside the CNS, CNP is found in Schwann cells of the peripheral 
nervous system (PNS), in some immune cells (Sprinkle et al., 1985), 
photoreceptor cells of the retina (Giulian and Moore, 1980), and testis (Scherer 
et al., 1994).  
CNP is an enzyme which was originally characterized by its ability to hydrolyze 
2’, 3’-cyclic nucleotides in vitro. CNP is found most abundantly in myelin of 
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oligodendrocytes in the CNS and to lesser extent in Schwann cells. The absence 
of a physiologically relevant substrate in myelinating oligodendrocytes or any 
other tissue indicates that catalytic activity is irrelevant for the role of CNP in 
vivo, therefore leaving the function of this enzyme unknown. Several, but 
rather divergent functions of CNP have been postulated in the literature. It was 
shown that CNP is involved in RNA metabolism (Heaton and Eckstein, 1996) 
supporting the rapid biogenesis of the myelin sheath (reviewed by (Sprinkle, 
1989). Other studies demonstrated a direct interaction of CNP with 
mitochondria in bovine adrenal cell cultures (McFerran and Burgoyne, 1997). It 
was also reported that CNP acts as a microtubule-associated protein and 
promotes microtubule assembly (C Laezza et al., 1997; Maurizio Bifulco et al., 
2002). The authors claim that phosphorylation of CNP interferes with its 
assembly-promoting activity, similar to the deletion of its carboxy terminus 
which leads to abnormal microtubule distribution within cells. Membrane 
localization of the protein and CNP-dependent microtubule organization suggest 
that CNP is a membrane-bound microtubule-associated protein that can link 
tubulin to membranes and may regulate cytoplasmic microtubule distribution.  
In this context, it was rather unexpected that Cnp1 deficient mice revealed no 
severe myelin phenotype. Cellular distribution of myelin proteins and myelin 
lipid content are not altered. Myelin spacing in the spinal cord and tubular 
networks within the oligodendrocytes also appeared to be unaffected by the 
loss of Cnp1 (Lappe-Siefke et al., 2003). The mice also showed no 
morphological developmental delay till the age of 2.5 months, except for 
abnormal enlargement of the inner tongue processes of myelin, which occurs 
concomitantly to the earliest axonal defects within days of myelination onset 
(Edgar et al., 2009). It has been shown that the distribution of nodal sodium 
channels and paranodal adhesion proteins becomes disorganized with age in 
Cnp1 deficient mice, suggesting a role of CNP in maintaining integrity of 
paranodes (Rasband et al., 2005). 
Many mice unexpectedly develop ataxia and hind leg impairments at the age of 
4 months, progressing until premature death between 9 and 15 months. This 
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phenotype was accompanied by axonal swellings at distal paranodal regions 
containing multivesicular bodies and cytoskeleton components and progressive 
axonal (but not neuronal) loss detected at the age of 7 months (Lappe-Siefke et 
al., 2003).  
Axonal changes in the Cnp1 knock-out mouse are characterized by focal 
accumulations of axonal organelles, being associated with impaired fast axonal 
transport and subsequent degeneration of the distal portions of long spinal 
axons.  
Therefore, Cnp1 null mutants serve in the present study as a model of ‘primary’ 
axonal loss, preceding the degeneration or retraction of myelin. 
3.2.1.2 Plp1 null mice – a model of axonal loss with mild myelin 
disorder 
Proteolipid protein (PLP) is the major CNS myelin protein, which is highly 
expressed in oligodendrocytes (I Griffiths, Klugmann, T. Anderson, D Yool, et 
al., 1998). The two protein isoforms PLP and DM20, originating from the Plp1 
gene, constitute together at least 50% of protein in CNS myelin (Lees MB and 
Brostoff SW, 1984). Unlike DM20, PLP expression is restricted to 
oligodendrocytes in the CNS (Braun, P.E., 1984).  
The systemic consequences of mutations or absence of PLP/DM20 have been 
widely studied in vivo, giving important insight into the function of PLP. The 
natural mouse mutants jimpy (Dautigny et al., 1986; K A Nave et al., 1986) and 
the allelic rumpshaker mouse (Schneider et al., 1992) bear mutations in the 
Plp1 gene and are models for the connate form of Pelizaeus-Merzbacher 
disease (PMD) and for hereditary spastic paraplegia 2 (SPG2) in humans, 
respectively. Dysmyelination and oligodendrocyte death are caused by the 
misfolded cytotoxic protein product in both the mouse models and the human 
patients (Skoff et al., 2004; I Griffiths, Klugmann, T. Anderson, Thomson, et al., 
1998). In contrast are the Plp1 null mutants not severly affected, with almost 
normal development of CNS white matter and no motor problems up to the age 
of 15 months (Boison et al., 1995; Rosenbluth et al., 1996; Klugmann et al., 
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1997). Myelin synthesis appeared to be normal and oligodendrocytes were 
viable and differentiated. This suggested that PLP and DM20 are not crucial for 
myelin assembly. Plp1-deficient mice develop a late onset axonal pathology  
(I Griffiths, Klugmann, T. Anderson, D Yool, et al., 1998), showing 
accumulations of organelles at distal juxtaparanodal regions similar to Cnp1 null 
mutants. Both models develop axonal pathologies upon oligodendroglial 
dysfunction, accompanied by impaired axonal transport and distal axonal 
degeneration. Mass spectrometry of Plp1-deficient myelin showed absence of 
Sirtuin-2 (Sir2), a NAD-depedent protein deacetylase that is under physiological 
conditions located to noncompacted myelin.  These findings demonstrate a 
potential role of PLP in proper transport of cargo proteins into the myelin 
compartment, which could influence axon function (Werner et al., 2007). 
Interestingly, axonal swellings in Plp1 and Cnp1 knock-out mice resemble those 
seen in other models for impairment of axonal transport such as paraplegin and 
spastin mutants (Edgar et al., 2004). Pathological analysis of myelin mutants 
indicates that oligodendrocytes modulate various processes within their 
myelinated axon beneath, including axonal transport (Witt and Scott T. Brady, 
2000). Providing a basis for regulation of axonal transport by OLs, localized 
changes in kinase and phosphatase activities occur at nodal/paranodal regions 
of myelinated axons, precisely the site at which axonal organelles accumulate in 
Plp1 knock-out mice. This suggests that localized deregulation of 
kinase/phosphatase activity and motor proteins might occur in the absence of 
various myelin-associated proteins. Such localized actions on motor proteins is 
supported by axonal transport impairment independent of changes in motor 
protein transcription (G Morfini et al., 2001; Gerardo Morfini et al., 2002; 
Gerardo Morfini et al., 2004). Another explanation for impaired axonal transport 
in myelin mutants are local energy deficiencies. This is consistent with axonal 
organelle accumulations observed in paraplegin-deficient mice, which are 
morphologically similar to those in myelin mutants (Gerardo A. Morfini et al., 
2009). 
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Fig. 3: Axonal transport abnormalities in myelin protein-deficient mice. 
(A) Schematic summarizing the changes that occur in axons in the Plp1 null mouse 
model of spastic paraplegia type 2. Despite almost normal myelination, axonal organelles 
accumulate at the distal juxtaparanodal regions of myelinated axons, eventually causing 
localized swelling of the axon. Axonal swellings are not preferentially localized to 
proximal or distal portions of an axon, and it is likely (though not confirmed) that a single 
axon contains multiple swellings. The distal portions of the long axons of the spinal cord 
eventually degenerate (represented by the dashed line). (B–E) Electron micrographs of 
CNS fiber changes. Organelle accumulation and cytoskeletal disruption in a myelinated 
axon from a P120 Plp1 null mouse spinal cord (B). Morphologically similar organelle 
accumulations in the spinal cord (C) and optic nerve (D) of P120 Cnp1 null mice. 
Swelling of the inner tongue process of the oligodendrocyte (asterisks in D and E) is a 
feature of the Cnp1 null mouse. The swollen tongue appears not to compress the axon but 
seems to be accommodated by expansion of the compact myelin sheath, as illustrated in 
these P120 optic nerve fibers. Scale bars: B, C, 2 µm; D, E, 1 µm. Figure from (Gerardo 
A. Morfini et al., 2009) 
Dysfunction and degeneration of different neuronal populations are features of 
adult-onset neurodegenerative diseases (AONDs) (Bossy-Wetzel et al., 2004; 
Mattson and Magnus, 2006). Despite their heterogeneous etiology, AONDs 
share several characteristics: they are progressive and their clinical phenotype 
results from an age-dependent decline in neuronal function that is initially 
associated with loss of synaptic activity rather than neuronal cell death, a late 
event in the disease process. Cnp1 and Plp1 null mutant mice reflect these 
disease hallmarks and can therefore be considered as model systems to study 
AONDs (Gerardo A. Morfini et al., 2009).  
It has thus far not been investigated how neurons, which develop age-
dependent axonal pathologies, react to the lack of glial support on a 
transcriptional level. Neurons deprived of oligodendroglial support may change 
their gene expression pattern in order to adapt to primary disease causing 
INTRODUCTION 
 
 17
changes. We addressed this question by expression profiling of a specific 
neuronal subpopulation in the cortex of Cnp1 and Plp1 null mutant mice. We 
therefore crossbred myelin mutants with the Thy1-EYFPnuc reporter mouse line 
(described in section …) and subjected Plp1-/Y, Cnp1-/-, and wild-type controls 
to LCM. 
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4 Objectives 
 
 
The main aims of the study were:  
(i) Characterization of reference transcriptional profiles of the main glial cell 
populations (Microglia, Astroglia and Oligodendroglia) from acutely isolated, 
FACS purified cells. 
(ii) Generation of transcriptional profiles of a cortical projection neurons and 
white matter tracts in mouse models, which show axonal degeneration caused 
by a dysfunction of oligodendrocytes. 
(iii) Generation of a model of the diseased transcriptional network underlying 
early adaptive events of axonal degeneration. 
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5.1 Materials 
5.1.1 Laboratory supplies and equipment. 
5.1.1.1 Equipment 
Picodrop Spectrophotometer Picodrop Limited
Agilent 2100 Bioanalyzer  Agilent Biotechnologies
7500 Fast Real-time PCR System  Applied Biosystems
Light Cycler 480 Roche
Biophotometer  Eppendorf
Heraeus Biofuge Fresco  DJB Labcare
Centrifuge 5810R Eppendorf
Thermocycler T3 Biometra
Thermocycler TGradient Biometra
Electrophoresis power supply Pharmacia LKB
UV Gel Documentation System iNTAS
Thermomixer comfort Eppendorf
Arium 611 Water Purification System  Sartorius
Leica DM IRBE inverted microscope Leica
Veritas Microdissection Instrument Molecular Devices
Cryotome CM3000 Leica
EpMotion pipette robot Eppendorf
Hybridization Oven 645 Affymetrix
Fluidics Station 450 Affymetrix
Scanner 3000 7G Affymterix
 
5.1.1.2 Software 
Windows XP Professional Microsoft
OSX Apple
Microsoft Office 2003  Microsoft
Acrobat Reader Professional 8.0 Adobe
Endnote X2  Thomson Research Soft
Creative Suite CS3 Adobe
Lasergene 7.0.0 DNA Star Inc.
Vector NTI Advance 10 Invitrogen
MicroWin 2000 Berthold Technologies
R.2.6 (statistical computing environment) http://cran.r-project.org/
Bioconductor Packages http://www.bioconductor.org/ 
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Partek Genomics Suite 6.4 Partek
GSEA 2.0 Broad Institute of MIT 
visANT http://visant.bu.edu 
GenePattern 2.0 Broad Institute of MIT 
Tinn-R SourceForge
ImageJ v1.41 http://rsbweb.nih.gov/ij/index.html
qBase v1.3.5 http://medgen.ugent.be/qbase/
Gene chip operating software Affymetrix
Bioconductor packages 
bridge affxparser goTools mouse4302cdf 
Biostrings ade4 graph mouse4302probe 
biomaRt ABarray GraphAlignment mouse430a2.db 
bioDist DBI graphics mouse430a2cdf 
biocViews EMV GSEABase mouse430a2probe 
base exonmap gtools multtest 
ArrayTools feature Heatplus oligo
AnnotationDbi fields KEGG.db pdInfoBuilder 
annotate gcrma keggorth plier
AnnBuilder gdata limma R2HTML 
annaffy genefilter maanova RankProd 
affyQCReport GeneMeta made4 RColorBrewer 
affyio geneplotter makecdfenv RMySQL 
affydata geneRecommender makePlatformDesign siggenes 
affycoretools GeneSelector marray simpleaffy 
AffyCompatible GEOmetadb maSigPro
affycomp GEOquery MASS
affy GOstats mouse4302.db
5.1.1.3 Plasticware 
General laboratory materials from Eppendorf, Falcon, Gilson and ABgene were 
used for molecular biology applications. For cell culture applications plastic 
wear from Falcon and Nunc was used. 
Kits:    
QIAprep Spin Miniprep Kit  Qiagen 
QIAquick Gel Extraction Kit  Qiagen 
QIAfilter Midi und Maxi Kit  Qiagen 
T7 Megascript Kit Ambion 
Transcriptor High fidelity cDNA Synthesis Kit Roche 
cDNA Pre Amplication Kit Roche   
SuperScript III First Strand Synthesis Kit Invitrogen 
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RNeasy Mini Kit  Qiagen
RNeasy Micro Kit  Qiagen
RNase-Free DNase Set Qiagen
Deoxynucleoside Triphosphate Set Roche
WT-Ovation Pico System Nugen
FL-Ovation cDNA Biotin Module Nugen
WT-Ovation Exon Module Nugen
GeneChip WT sense Target Labeling Kit Affymetrix 
5.1.1.4 Reagents 
General reagents 
General chemicals from Sigma-Aldrich or MERK were used unless stated otherwise. 
Agarose Applichem
Agar BD
GeneRuler 1 kb DNA ladder Fermentas
GeneRuler 100 bp DNA ladder  Fermentas
6x DNA Loading Dye Fermentas
Power SYBR Green PCR Master Mix Applied Biosystems
Trizol reagent Invitrogen
Acetonitryl J.T.Baker
Fomamide Sigma-Aldrich
SSPE buffer (20x) AppliChem
Salmon Sperm DNA Sigma-Aldrich
Yeast tRNA Sigma-Aldrich
SSPE buffer (20x) AppliChem
Universal probe library (Mouse) Roche
Enzymes 
Restriction enzymes  New England Biolabs
REDTaq DNA polymerase Sigma-Aldrich
Taq polymerase Roche
T4 DNA ligase Promega
Superscript III Reverse Transcriptase Invitrogen
Power SYBR green PCR master mix  Applied Biosystems
TaqMan PCR master mix Applied Biosystems
5.1.1.5 Microarrays 
Mouse430A 2.0 Affymetrix
Mouse Exon 1.0 ST Affymetrix
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5.1.1.6 Molecular biology buffers 
dNTP-stock solutions (100 mM) 
25 mM each dATP, dCTP, dGTP, dTTP (Boehringer, Mannheim) 
Ethidiumbromide 
1-1.5 μg/ml for agarose gels in 1x TAE 
TAE (50x, 1000ml) 
2 M Tris-Acetate, pH 8.0 
50 mM EDTA 
57.1 ml Glacial acetic acid 
Add dH2O up to 1000ml 
TE (1x) 
10 mM Tris-HCl, pH 8.0 
1 mM EDTA 
Modified Gitschier buffer (MGB, 10x) 
6.7 ml 1 M Tris-HCl (pH 8.8) 
1.66 ml 1 M (NH4)2SO4 
650 μl 1 M MgCl2 
Add dH2O up to 10 ml 
MGB buffer (1x, working solution) 
1 ml 10x MGB 
100 μl β-Mercaptoethanol 
500 μl 10 % Triton X-100 
8.4 ml dH2O 
5.1.1.7 Protein biochemistry buffers 
Lysis buffers 
Lysis buffer I (for brain) 
50 mM Tris-HCl, pH 7.5 
150 mM NaCl 
1 mM EDTA 
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1 % Triton X-100 
1 mM PMSF (add before use) 
1 tablet Complete Mini protease inhibitor (Roche)/ 10 ml of lysis buffer 
* protease inhibitors are added freshly to the lysis buffer before use 
5.1.1.8 Protein purification buffers 
Wash buffer I (WB I) 
10 mM Tris, pH 7.5 
150 mM NaCl 
0.05 % Tween-20 
10 mM EDTA 
Adjust pH to 7.5 
Wash buffer II (WB II) 
50 mM Tris, pH 7.5 
Elution buffer I (EB I) 
0.1 M Glycine, pH 3.0 
Elution buffer II (EB II) 
0.1 M Glycine, pH 2.5 
Neutralization buffer (NB) 
1 M Tris, pH 8.0 
5.1.1.9 SDS PAGE and Western Blotting 
Separating SDS gel (12 %, 4 gels, 1.5 mm thickness) 
13 ml dH2O 
15 ml 30 % Acrylamide (BioRad, 29.1) 
9.4 ml 1.5 M Tris-HCl (pH 8.8) 
370 μl 10 % SDS 
125 μl 10 % APS (Ammonium persulfate) 
30 μl TEMED (BioRad) 
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Stacking SDS gel (4 gels) 
6.1 ml dH2O 
1.3 ml 30 % Acrylamide (BioRad, 29.1) 
2.5 ml 0.5 M Tris-HCl (pH 6.8) 
100 μl 10 % SDS 
50 μl 10 % APS (Ammonium persulfate) 
10 μl TEMED 
SDS running buffer (Laemmli buffer, 1x) 
25 mM Tris-HCl 
192 mM Glycine 
1 % (w/v) SDS 
SDS sample buffer (6x) 
7 ml 0.5M Tris-HCl buffer (pH 6.8) 
3 ml Glycerol (30 % final concentration) 
1 g SDS 
1.2 ml 1 % Bromophenol blue 
0.2 - 2 % β-Mercaptoethanol (add fresh) 
Transfer buffer (1x) 
48 mM Tris base 
39 mM Glycine 
10-20 % Methanol 
Blocking Buffer 
5 % non-fat dry milk powder in TBS or PBS (1x) 
Western blot stripping buffer 
0.2 M Glycine-HCl, pH 2.5 
0.1 % Tween-20 
Coomassie blue (Staining solution) 
2 g Coomassie brilliant blue (R-250) 
1 l Methanol 
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200 ml Acetic acid 
800 ml dH2O 
Stir overnight and filter through Whatmann paper. 
Destaining solution 
50 ml Methanol 
10 ml Acetic acid 
40 ml dH2O 
Tris buffered saline (TBS, 20x) 
1 M Tris base 
3 M NaCl 
Adjust pH 7.4 (with HCl) 
TBS with Tween-20 (TBST, 1x) 
50 mM Tris-HCl (pH 7.4-7.6) 
150 mM NaCl 
0.05 % - 0.15 % Tween-20 
5.1.1.10 DNA and Protein markers 
GeneRuler 1 kb DNA ladder (Fermentas) 
GeneRuler 100 bp DNA ladder (Fermentas) 
Precision Plus prestained protein standard (BioRad) 
5.1.1.11 Immunocytochemistry buffers 
Phosphate buffered saline (PBS) (1x cell culture, 1000 ml) 
136 mM NaCl 
2.6 mM KCl 
10 mM Na2HPO4 x2 H2O 
1.4 mM KH2PO4 
Set pH to 7.2 with 10 N NaOH 
Add dH2O up to 1000 ml 
4 % Paraformaldehyde in PBS/TBS 
100 ml 0.2 M NaH2PO4 (Sodiumdihydrogenphosphate) 
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400 ml 0.2 M Na2HPO4 (di-Sodiumhydrogenphosphate) 
108 ml 37 % Formalin 
392 ml dH2O 
Filtered with a 500 ml Nalgene sterile filter unit 
Blocking Buffer 
2 % BSA (Fraction V) 
2 % Goat serum 
0.02 % Biotin 
0.1 % Porcine skin gelatine 
0.01 % Saponin 
Dissolved in TBS or PBS 
Mounting Agent 
Aqua polymount (Polysciences) 
5.1.1.12 Immunohistochemistry buffers 
Phosphate buffer (stock solution) 
0.2 M NaH2PO4 
0.2 M Na2HPO4 
Phosphate buffer (working solution, pH 7.4) 
20 ml 0.2 M NaH2PO4 
80 ml 0.2 M Na2HPO4 
100 ml dH2O 
Bovine Serum Albumin (PBS/BSA) 
20 ml 0.2 M NaH2PO4 
80 ml 0.2 M Na2HPO4 
1.8 g NaCl 
1 g BSA 
100 ml dH2O 
Citrate Buffer (stock solution)* 
0.1 M Citric acid (C6H8O7*H2O) 
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0.1 M Sodium citrate (C6H5O7Na3*2H2O) 
*Stored at 4°C 
Citrate Buffer (working solution, 0.01 M, pH 6.0)* 
9 ml 0.1 M Citric acid (C6H8O7*H2O) 
41 ml 0.1 M Sodium citrate (C6H5O7Na3*2H2O) 
450 ml dH2O 
*Always freshly prepared 
Tris Buffer (stock solution)* 
0.5 M Tris base 
Adjust pH 7.6 with HCl 
*Store at 4°C 
Tris Buffer (working solution)* 
100 ml 0.5M Tris base (pH 7.6) 
9 g NaCl 
Add up to 1000 ml with dH2O 
*Always freshly prepared 
Blocking buffer (2 % milk powder in Tris Buffer) 
20 g of non-fat milk powder 
Add up to 1000 ml with Tris buffer 
5.1.1.13 Histological stains and reagents 
Mayer’s Haematoxylin solution 
1 g Haematoxylin (Merck) was dissolved in 1000 ml dH2O and 0.2 g sodium iodate and 
50g potassium aluminium sulphate (K2Al2(SO4)4*24H2O) was added under constant 
shaking. Finally, 50 g chloralhydrate and 1 g citric acid were added and the solution 
was filtered before use. 
Eosin solution 
Stock solution (10x) 
10 g of Eosin were dissolved in 100 ml of dH2O and left to mature. 
Working solution 
2.5 ml stock solution 
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250 ml dH2O 
12 drops glacial acetic 
Scott’s solution 
2 g KHCO3 (potassiumhydrogencarbonate) 
20 g MgSO4 (magnesium sulphate) 
Add up to 1000 ml with dH2O 
Thionin solution 
Stock 1.3% thionin: 
13 gm Thionin 
1000 ml dH2O 
Stir and heat gently for 1 hour. Filter the solution after the dye has dissolved. Store in 
a stoppered bottle.  
Buffers: 
1. 1 M Acetic Acid (HAc): 
58.5 ml glacial acetic acid 
dilute to 1 liter with distilled water 
2. 1 M Sodium Hydroxide (NaOH): 
50 gm sodium hydroxide pellets 
dissolve to 1 liter with distilled water 
Working Stains (1%): 
80.0 ml 1M HAc 
14.4 ml 1M NaOH 
305.6 ml Thionin stock 
HCl- Alcohol 
1.25 ml HCl 
350 ml Ethanol 
150 ml dH2O 
Staining solution 
Eosin solution 
MATERIALS AND METHODS 
 32
0.1 g Eosin was dissolved in 100 ml dH2O and 0.1 g methylene blue in 100 ml dH2O. 
The  two solutions were mixed and left for 3-4 days to mature. The solutions were 
filtered through Whatmann paper, let to dry over night and then dissolved in 10 ml 
pure methanol. The solution was stored at 4°C. 
Staining solution 
Dissolve 1 g of Luxol blue (1B, MBS from Chroma) in 1000 ml 96 % ethanol while 
stirring and warming. Let the solution cool down at room temperature and filter though 
Whatmann paper. Before use, for every 100 ml of staining solution add 50 μl of 
concentrated acetic acid (CH3COOH). 
‘Nuclear fast red’ solution 
Dissolve 0.2 g of ‘nuclear fast red’ in 200 ml of boiling 5% aluminium sulfate solution 
and boil for an additional 5-10 min. Let it cool down at room temperature and filter 
with Whatmann paper. 
5.1.1.14 Mouse lines 
CNP null mutants (Lappe-Siefke et al., 2003) 
PLP null mutants (Klugmann et al., 1997) 
Thy1-EYFPnuc (Rossner et al., 2006) 
hGFAP-EGFP (Nolte et al., 2001) 
CX3CR1-EGFP (Jung et al., 2000) 
PLP-DsRed (P.G. Hirrlinger et al., 2005) 
5.1.1.15 Oligonucleotides 
Oligonucleotides were synthesized in the Max Planck Institute of Experimental 
Medicine. 
Genotyping primers for various mouse lines 
Thy-1 EYFPnuc Forward: Forward: CGGCTACGGCCTGCAGTGCT,
 Reverse: Reverse: GGCGGATCTTGAAGTTCACCTTGATG. 
 Amplification product: 200 bp
   
Cnp1 puro3: CATAGCCTGAAGAACGAGA
 Forward: GATGGGGCTTACTCTTGC
 Reverse: GCCTTCAAACTGTCCATCTC
 Amplification product: 600 bp for mutant and 900 bp for wild-type 
   
Plp1 Forward: GGAGAGGAGGAGGGAAACGAG 
 Reverse: TCTGTTTTGCGGCTGACTTTG
 Neo: TTGGCGGCGAATGGGCTGAC
 Amplification product: 300 bp for mutant and 150 bp for wild-type 
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Quantitative real-time PCR primers 
Actb Forward: ACGGCCAGGTCATCACTATTG 
 Reverse: AGGAAGGCTGGAAAAGAGCC 
 Hydrolysis Probe CAACGAGCGGTTCCGATGCCC 
  
Atp5b Forward: GGCACAATGCAGGAAAGG    
 Reverse: TCAGCAGGCACATAGATAGCC 
 Hydrolysis Probe CCAAGGGTGGGAAAATCGGACTCTTTG 
  
Med1 (var1) Forward: ACGAGGGACGAGGAAGTTG 
 Reverse: TCTGGTTAAATTTTGCATGGAG 
 UPL probe: #79 (cat. no. 04689020001) 
  
Rock2 Forward: AGTCCCTGGGTAGTTCAGCTC 
 Reverse: GCCTGGCATGTACTCCATC 
 UPL probe: #98 (cat. no. 04692152001) 
  
Pttg1 Forward: GAAAAGTTCTTCCCTTTCAATCC 
 Reverse: TTCATTCAGGGTCATGAGAGG 
 UPL probe: #7 (cat. no. 04685059001) 
  
Krt12 Forward: GCGACGGTTTTGACGAGA
 Reverse: TTTTTCGAGTTTTATTTGGGTCTT 
 UPL probe: #94 (cat. no. 04692110001) 
Antibodies 
Primary antibodies directed against 
Antibody Species Company Dilution Purpose 
GFAP Mouse Novocastra 1:200, IHC 
CC1 (APC) Mouse Calbiochem 1:50, IHC 
IBA1 Rabbit Wako 1:200, IHC 
NeuN Mouse Chemicon 1:500, IHC 
5.2 Methods 
5.2.1 Animals 
All experiments were performed in accordance with the federal law and on approval of 
the animal care committee of the Bezirksregierung Braunschweig, Germany. Mice were 
housed under a 12 h light/dark cycle (lights on at 5:00 A.M.) with food and drinking 
water available ad libitum. 
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5.2.2 Tissue preparation for time course study  
EYFPnuc under Thy-1  promoter expressing transgenic mice were generated by Moritz 
Rossner at the ZMBH in Heidelberg (Rossner et al., 2006); referred to as TYNC. Cnp1 
null mouse line (Cnp1-/-) was generated by Corinna Lappe-Siefke at the Department of 
Neurogenetics, Max Planck for Experimental Medicine, Goettingen (Lappe-Siefke et 
al., 2003). The hemizygous Plp1-knockout mice (Plp1-/Y) were generated by Matthias 
Klugmann at ZMBH, University of Heidelberg (Klugmann et al., 1997). TYNC mice 
were crossed with WT, Cnp1 null and Plp1 null mice to generate following genotypes: 
WT (controls) TYNC +/-, Cnp1 +/+, Plp1 +/y
Cnp-/- TYNC +/-, Cnp1 -/-, Plp1 +/y
Plp -/y TYNC +/-, Cnp1 +/+, Plp1 -/y
 
For this study 1, 3, 6 and 12 month old male Cnp1-/-, Plp1-/Y and age-matched control 
mice (n = 3/genotype) were sacrificed by cervical dislocation. To reduce biological 
variation, all mice were processed between 9 and 10 h after light onset. Brains were 
removed from the skull and bisected along the midline using a razorblade. One half 
was frozen on dry ice, sealed with parafilm and stored at –80°C until further use and 
the other half was post immersion fixed in 4% paraformaldehyd (PFA) for 48 hours 
and paraffin embedded (Fig. 4).  
 
Fig. 4: Mouse brain preparation scheme 
Scheme depicts procedure for tissue sampling. For immunohistochemical analysis (left 
panel) and for laser capture microdissection (right panel). 
5.2.3  Preparation of mouse genomic DNA for genotyping 
For the preparation of mouse genomic DNA for genotyping, 2-3 mm of the tail were 
cut and placed in microcentrifuge tubes. 180 μl of 1x MGB and 20 μl of proteinase K 
(10 mg/ml) were added to each tube and incubated at 55ºC overnight with vigorous 
shaking. Once the tails were dissolved, proteinase K was heat-inactivated by incubating 
the DNA lysate at 95ºC for 10 min. Then, the DNA lysate was centrifuged at 13.000g 
for 1 min to pellet all the undigested material and the supernatant was collected in 
fresh tubes. 1-2 μl of this diluted DNA preparation was used for genotyping PCR 
amplification. 
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5.2.4 Genotyping polymerase chain reaction (PCR) 
PCR-Mix:  
 TYNC Cnp1-/- Plp1-/Y 
DNA 1 1 1 
Fwd Primer 0,2 0,5 0,5 
Rev Primer1 0,2 0,5 0,5 
Rev Primer2 1 0,5 
NTP 2 2 2 
Buffer (5x) 4 4 4 
DMSO 1 1 1 
Go Taq 0,2 0,2 0,2 
H2O 11,4 9,8 10,3 
Program #1 #2 #1 
 
PCR program #1: 
95°C 3´
56°C 30´´
72°C 1´ 36x
95°C 30´´
56°C 1´
72°C 10´
4°C Pause
 
PCR program #2: 
95°C 3´
50°C 30´´
72°C 90´´ 36x
95°C 30´´
50°C 1´
72°C 10´
4°C Pause
5.2.5 Preparation of CNS cryosections for LCM 
Serial coronal brain sections at the level of the striatum (bregma 1 mm to 0.5 mm), 
were prepared using a cryostat (Leica) at –18°C and were mounted on Starfrost glass 
slides (Sigma Aldrich) for single cell isolation (8 µm thick sections) and for micro region 
isolation (20 µm thick sections) on PEN-membrane slides (Molecular Devices). Once 
the first section had been mounted, the slide was kept inside the cryochamber (-18°C) 
MATERIALS AND METHODS 
 36
while the next section was cut. Eight to twelve sections were mounted in this way on 
each slide. Cutting and mounting was performed as quickly as possible to ensure that 
all sections adhered properly to the membrane. Two slides were prepared at a time 
and processed in parallel. After sectioning, the slides were stored on dry ice until 
dehydration and staining. 
Sections mounted on PEN slides (for micro region isolation) were stained prior to 
dehydration. Slides were fixed in 70% EtOH for 30 sec, rehydrated in H2O for 10 sec 
stained in 2% thionin staining solution (Sigma) washed two times in fresh H2O. For 
dehydration sections were subsequently fixed in 70% EtOH for 30 sec, followed by a 
dehydration series in 95% EtOH for 30 sec, two times ‘freshly’ pured 100% EtOH for 
one min. and two times Xylene for two min. After dehydration slides were air dried, 
transported and kept in a box with desiccant. Sections for single cell isolation were 
only subjected to dehydration procedure. We used only precooled RNAse free 
plasticware and solutions;  
5.2.6 Laser capture microdissection 
The EYFP+ cells were microdissected from the motor and somatosensory cortex from 
10 slides in total; we used the HS Transfer Caps (Molecular Devices) to capture 
between 100 and 300 neurons per cap, for a total sample size between 700 and 800 
microdissected neurons. The corresponding CC-WM microregions were microdissected 
from 10 adjacent slides and were also pooled. For the microdissection, we used the 
Arcturus Veritas microdissection system with fluorescence package (Molecular 
Devices). The isolation of EYFP+ cells was done by identifying single bright fluorescent 
cells in the fluorescence mode. Cells were only collected if no adjacent nuclei were 
detected in close proximity. Successful cutting and collection steps were subsequently 
validated in bright-field and fluorescent mode on the quality control slot of the device. 
Microdissected samples were lysed in 100 µl of RNA lysis buffer (Qiagen, Hilden, 
Germany) byvigorous vortexing for 30 sec and stored at -80°C until further use. All 
procedures were done under RNAse-free conditions. 
5.2.7 Fluorescent-activated cell sorting (FACS)  
To increase purity of microglia, oligodendrocytes and glial precursors cells, cells were 
sorted using transgenic animals that express fluorescent proteins under cell type 
specific promoters. More specific, heterozygous Cx3cr1-EGFP, Plp-DsRed and hGFAP-
EGFP mice were used for FACS. The forebrain was isolated by removal of the olfactory 
lobes, cerebellum, and midbrain/hindbrain structures by crude dissection, and the 
tissue was diced with a curved-blade surgical scalpel. To isolate cerebral cortical gray 
matter cells the brain was sliced in 2-3 mm coronal sections and the cerebral cortex 
was carefully dissected away from the ventral white matter tracks. This tissue was 
enzymatically dissociated to make a suspension of single cells, essentially as described 
by (Giulian and Baker, 1986). Cortex samples were incubated with 2 ml HBSS 
(containing Mg2+), 1 ml trypsin and 1 ml 0.05% DNase at 37°C for 10 min. The cell 
suspension was then triturated with a 10 ml pipette and incubated at 37°C for another 
10 min. The same step was repeated with a 5 ml pipette and a glass Pasteur pipette. 
The cell suspension was then centrifuged for 10 min at 800 rpm and the cell pellet was 
resuspended with 3 ml Mg2+-containing HBSS. After filtration through a nylon 40 μm 
cell filter (BD Falcon), the cell suspension was incubated with 80 μl of PI (stock 1 
mg/ml, Sigma) and 4 μl Hoechst (stock 5 mg/ml, Sigma) at 37°C for 20-30 min. 
Propidium iodide (PI) intercalates into double-stranded nucleic acids; it is excluded by 
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viable cells but can penetrate the cell membranes of dying or dead cells. Hoechst 
33342 is also a non-toxic membrane-permeable dye that intercalates in the DNA and is 
used to stain living cells. 5 ml of HBSS were then added and the pellet resuspended in 
10 ml of glial culture medium. The cell suspension was kept on ice until it could be 
sorted in a BD FACSAria™ cell sorter with the right filters and based on the 
manufacturer’s instructions (BD Biosciences). 
5.2.8 RNA isolation and quantification 
5.2.8.1 RNA purification (100ng–5µg) 
‘RNeasy mini preps’ (Qiagen) were used to purify the total RNA from e.g. FACS-sorted 
microglia, glial precursor cells and oligodendroytes as well as for brain lysates. Total 
RNA was purified following the manufacturer’s instructions. In brief, cells or tissue 
were lysed in RLT buffer and kept at -20°C until further use. The samples were thawed 
quickly by incubating them at 37°C in a water bath and further homogenized by 
vigorous vortexing for 1 min. 100% EtOH was added to provide the appropriate 
binding conditions, and the homogenates were applied to RNeasy mini columns where 
the total RNA binds to the membrane and the contaminants are efficiently washed 
away. The RNAs were eluted from the column with 100 μl of RNase-free ddH2O. 
5.2.8.2 Small scale RNA purification (500pg-100ng) 
For isolation of minute amounts of total RNA (100pg - 100ng) the RNeasy micro kit 
(Qiagen) was used according to manufacturer’s instructions. Same modifications as for 
standard RNA purification were applied (Section 5.2.8.1). 
5.2.8.3 Precipitation of RNA 
2 μl of Pelletpaint (Calbiochem) carrier were added to 100 μl of RNA. Pelletpaint builds 
a meshlike matrix which pulls precipitated RNA down and facilitates later visualization 
of pellet. After vigorous vortexing for 20 sec, 50 μl of 7.5 M NH4Ac were added, 
vigorous  vortexed for 20 sec and 360μl of 100 % EtOH was added to the RNA 
mixture. The RNA solution was centrifuged for 30 min at maximum speed with a table 
micro centrifuge at 4°C. The supernatant was discarded, the pellet was washed with 
300 μl of 70% ethanol centrifuged at full speed for 10 min, supernatant discarded the 
pellet was left to air dry at RT. X μl of RNase-free ddH2O was added to the pellet and 
put on ice for a further 15 min to dissolve. 
5.2.8.4 Quantification of RNA 
Quality and concentration of RNA were examined with the Nano labchip and the 
Bioanalyzer2000 (Agilent). Quantity and purity was also determined using a Picodrop 
Spectrophotometer (Picrodrop Limited). 
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5.2.9 cDNA synthesis 
5.2.9.1 Standard protocol for 30 ng – 2 μg total RNA 
cDNA synthesis is based on the characteristic feature of eukaryotic messenger RNAs to 
harbour the defined polyadenylated tail on the 3′ end. First-strand cDNA was 
synthesized for quantitative real-time PCR (QRT-PCR). Total RNA was mixed with 2 μl 
of random nonamer (200 pmol/μl) and 2 μl of oligo-dT (0,5 pmol/μl) primers. The 
mixture was heated to 70°C for 5 min and then incubated on ice for 2 min. 4 μl of 5x 
First-Strand buffer, 2 μl of 0.1 M DTT and 1 μl of 10 mM dNTPs were added to the 
mixture and the final volume was adjusted with dH2O to 19 μl. Finally 1 μl of 
SuperScript™ III RT (200 units/μl) was added to complete the synthesis reaction 
mixture. This mixture was incubated in the thermocycler at 25°C for 10 min, then 50°C 
for 30 min, 55°C for 30 min. Finally the reaction was terminated by heating to 70°C for 
15 min and further incubation on ice. The cDNA was used later as a template for 
amplification in PCR. 
5.2.9.2 Pre amplification protocol for 0,5 ng - 30 ng total RNA 
For minute amounts of RNA amplfication step is mandatory prior to perform QRT-PCR. 
Therefore cDNA synthesis was performed with a linear PCR amplification step. We used 
the Pre-Amplification kit (Roche) for amplification. Amplified cDNA yield was between 1 
– 3 µg for LCM samples. The protocol supplied by manufacturer was exactly followed.  
5.2.10 Quantitative real-time PCR for mRNA expression 
5.2.10.1 SYBR green Assays 
For each SYBR green assay, 5 μl of SYBR green master mix, 1 pmol of each forward 
and reverse primer pair, 1 μl of dH2O and 4 μl of cDNA mixture were mixed in a 96-
well plate. Real-time PCR was carried out using SYBR Green Master Mix according to 
the manufacturer’s instructions. 
5.2.10.2 Hydrolysis Probe Assays 
For hydrolysis probe assays the same protocol as for SYBR green assays was followed 
with the exceptions of using Taqman chemistry instead of SYBR green and addition of 
1 pmol of assay specific hydrolysis probe. Probes from the Universal Probe Library 
(Roche), were used for most assays.  
QRT-PCR was performed using either the 7500 fast real-time PCR system (Applied 
Biosystems) or the Light Cycler 480 (Roche). The PCR reaction was carried out for 40 
cycles in the following temperature conditions: ten sec at 95ºC, 25 sec at 60ºC and 35 
sec at 72ºC. The data acquisition was done at 72ºC. Relative expression analysis was 
calculated with ddCT method (Pfaffl, 2001) and was performed using the excel-based 
QRT-PCR analysis macro qBase (Hellemans et al., 2007). The results are depicted as 
bar graphs of normalized relative values with lowest value standardized to 1. Error bars 
represent standard deviation (SD). 
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5.2.11 Amplification for microarray hybridization 
3’ Expression arrays 
Total RNA of pooled single cells or micro-regions was resuspended with pretested T7-
tagged dT21V oligonucleotides. Two-round T7-RNA polymerase-mediated linear 
amplification was performed according to optimized protocols for low-input RNA 
amounts (see Small Sample Target Labeling Assay Version II; Affymetrix). Biotin-
labeled second-round aRNA was generated with a NTP-mix containing Biotin-11-CTP 
and Biotin-16-UTP (PerkinElmer, Boston, MA) (2 mM f.c.). Biotin-labeled amplified RNA 
(aRNA) size distribution and quantity was analyzed with the Agilent 2100 Bioanalyser 
using the RNA 6000 Nano LabChip kit (Agilent Technologies, Boeblingen, Germany). 
Samples with lower size compressed RNA products were discarded. 
Whole transcript (WT) Exon / Gene microarrays 
Total RNA (0.5 ng – 10 ng) was amplified using the WT-Ovation Pico RNA Amplification 
System V1 (Catalog # 3300–12; NuGen) and labeling with FL-Ovation cDNA Biotin 
Module V2 (Catalog #4200–12; NuGen) according to the protocol provided by the 
supplier.  
5.2.12 Microarray hybridization.  
3’ Expression arrays 
At least 5 µg of labeled cRNA was fragmented by heating the sample to 95°C for 35 
min in a volume of 20 µl containing 40 mM Tris acetate, pH 8.1, 100 mM KOAc, and 30 
mM MgOAc. Fragmentation was checked by alkaline agarose electrophoresis. 
Hybridization, washing, staining, and scanning were performed under standard 
conditions as described by the manufacturer. Mouse430A 2.0 genechips were used 
that contain over 22,600 probe sets representing transcripts and variants from over 
14,000 well-characterized mouse genes. 
Whole transcript (WT) Exon / Gene microarrays 
At least 10 µg of labeled cDNA was hybridized to WT microarrays. Design of WT 
microarrays are listed in Table 1. Hybridization, washing, staining, and scanning were 
performed under standard conditions as described by the manufacturer.  
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Table 1: Summary of WT microarray design 
 HuGene 
1.0ST 
MoGene 
1.0ST 
 MoExon        
1.0ST 
Number of Probes 764'885 770'317 1.4 million (core) 
 - - 2 million 
(extended) 
 - - 2,1 million (full) 
Number of Probe sets 28'869 33'252 54'675 
Number of Probe sets 27'901 27'547 28'206 
Number of Probe sets 206'728 208'644 219'230 
5.2.13 Microarray data analysis 
5.2.13.1 Analysis for 3’ expression microarrays 
Microarray raw data (.cel files) were exported using Gene chip operating software 
(gcos) (Affymetrix). Normalization and higher-level analysis were done in R 
environment employing affy, simpleaffy, limma and several other packages 
downloaded from Bioconductor (detailed list see section 5.1.1.2). Data normalization, 
filtering and determination of significance cut-offs were performed following rigorous 
standards, optimized to achieve a minimum of false positive discoveries. Briefly, 
normalization was carried out using the Robust Multichip Average (RMA) model 
implemented in the R package Affy, using default settings. The normalized microarray 
data was quality controlled (box-plot analysis, principal component analysis, and 
Spearman correlation tree) which led to the exclusion of two microarrays. The 
remaining data were re-normalized, log transformed and filtered based on  
1) Absolute expression values, meaning probe sets were rejected where absolute 
signal intensity were below 100 
2) Fold change (FC); probesets with a FC higher than 1.5 were included in further 
analysis for single gene analysis. A FC threshold of 1.3 was applied for further pathway 
level analysis using gene set enrichment analysis (GSEA; 
www.broadinstitute.org/gsea/). 
K-mean Clustering 
For K-means clustering we identified significant genes by 2-way ANOVA (phenotype 
over time, P-val < 0.001, average expression > 2 * SD). Expression values of filtered 
genes were transformed in order to evaluate the overall expression profiles regardless 
of fold change and absolute expression. We defined the arithmetic mean of each gene 
over all samples as 0 and the SD was set to 1. K-means clustering was performed to 
obtain 9 clusters using default settings in R ('stats' package).   
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Network integration and visualization 
We used the Gene Ontology (GO) (http://www.geneontology.org/) and Kyoto 
Encyclopedia of Genes and Genomes KEGG databases 
(http://www.genome.jp/kegg/pathway.html) to functionally annotate the gene cluster 
that were obtained by K-means clustering. We used the Visual Analysis Tool for 
Biological Networks and Pathways (VISant, version 3.68) http://visant.bu.edu/) to 
integrate and visualize selected gene set clusters of CPNs from Cnp1 null mice. We 
used the VISant-database predictome of protein linked interactions to connect nodes 
based on published interactions (referred to as ‘edges’ and drawn as straight and 
undirected lines between respective nodes). We used the information available for the 
human protein collection (containing > 90.000 entries compared to the mouse 
collection with only roughly 6,000 entries) that has been extracted from several large-
scale experimental and literature extracted databases (see http://visant.bu.edu/ for 
interaction statistics and methods selected). 
5.2.13.2 Analysis for whole transcript (WT) microarrays 
All array data obtained from WT platforms were analyzed with Partek Genomic Suite 
v6.4 (www.partek.com). Data was pre-processed, which included probe level RMA 
background correction, quantile normalization across all arrays, and Log2 
transformation followed by median polish to summarize probes to obtain the overall 
score for each probe set. The data were filtered based on the expression values of 
each probe set within the replicate set for each sample; if the expression value of a 
probe set was below 3.5 (log2 value) in all samples, the probe set was removed from 
the analysis. In order to identify probe sets that were significantly different between 
samples A and B, a one-way anova statistical test was performed on normalized and 
filtered probe set level intensities between each group to generate p-value and fold 
change values. Exon level analysis was performed with the 'exonmap' package in R 
using default settings. 
5.2.14 Protein biochemical methods 
5.2.14.1 Lysis of brains 
Wild-type and mutant mice were sacrificed by spinal cord dislocation and decapitated. 
The brains were removed and immediately put on a precooled brainslicer. Brains were 
coronally cut in 500μm sections. Sections from Bregma -1 mm to +1 mm were washed 
with PBS and further macrodissected with precooled spates. Somatosensory- and 
motor cortex (Cx), white matter tracts (WM) and hippocampus were isolated, frozen on 
dry ice and stored at -80°C. Micro-regions were thawed in 1ml PBS and homogenized 
using an Ultraturrax (T8) on highest settings (20-30s). 600 μl brain lysate were 
removed and combined with 1 ml RLT buffer for further RNA isolation. For protein 
isolation 600 μl of 2x Ripabuffer was added to the remaining brain lysate and further 
subjected to the tissue homogenizer for two times 20 sec on ice. Protein samples were 
incubated for 20-30 min on ice, the insoluble cellular debris were pelleted by 
centrifugation at 2000 rpm at 4ºC for 10 min and the supernatant was used for further 
analysis or stored at -70°C.  
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5.2.14.2 Quantification of protein concentration by Lowry assay 
The protein concentrations were determined using the Bio-Rad DC Protein Assay kit 
according to the manufacturer’s 'microplate assay' protocol. The working principle of 
the kit is similar to the Lowry assay (LOWRY et al., 1951). The absorbance was 
measured at 650 nm in a Mithras (Berthold) multiplate reader. The assay is based on 
the reaction of proteins with an alkaline copper tertrate solution and folin reagent, 
which leads to the loss of 1, 2, or 3 oxygen atoms, producing one or several reduced 
species that have a characteristic blue colour with maximum absorbance at 750 nm. 
The colour development is primarily due to the amino acids tyrosine and tryptophan, 
and, to a lesser extent, cystine, cysteine and histidine (LOWRY et al., 1951). 
5.2.14.3 SDS polyacrylamide gel electrophoresis 
The proteins were separated using the discontinuous SDS polyacrylamide gel 
electrophoresis (SDS-PAGE) described by Laemmli (Laemmli, 1970). The glass plates 
and the 1 mm spacers were assembled according to the Bio-Rad instructions. We used 
commercial twelve % separating gel solution of acrylamide. The chamber and the gels 
were assembled based on the manufacturer’s protocol. The protein lysates were 
diluted in 6x SDS sample buffer containing one % β-mercaptoethanol and heated for 
five min to 90°C. five μl of pre-stained Precision-plus (BioRad) was loaded on a well as 
a molecular weight standard. The gels were run at 10 mA/gel of constant current. After 
the bromophenol blue tracking dye entered the separating gel, the power was 
increased to 15 mA / gel. The electrophoresis was terminated once the bromophenol 
blue had reached the lower end of the gel. The gel was removed and preceded for 
Coomassie staining or protein blotting. 
5.2.14.4 Coomassie staining 
The gels were fixed for 15 min in 25 % isopropanol / 10 % acetic acid and then briefly 
washed with dH2O. After incubation in the coomassie blue staining buffer overnight, 
the gels were incubated with the destaining solution and scanned with an UMAX 
Astra47000 scanner. 
5.2.14.5 Western blotting (WB) 
Electrophoretic transfer 
Proteins were transferred from the SDS-gel onto a PVDF membrane 
(Amersham/Millipore, pore size 0.45 μm) by electrophoresis, as originally described 
with modification (Towbin et al., 1979). PVDF membranes were activated for 30 sec 
in 100 % methanol and further incubated in transfer buffer for 15 min. The gels, the 
Whatmannpaper and the blotting pads were pre-soaked in transfer buffer for 15-30 
min and further assembled according to the manufacturer’s protocol. Proteins were 
transferred at a constant voltage of 38 V and a maximum current of 275 mA for a 1.5 
mm gel and for 1.5-2 hrs at room temperature. 
Immunological detection of proteins on PVDF membranes 
After electrophoretic transfer, the membranes were blocked for 1 hr at room 
temperature in blocking buffer (five % non-fat dry milk in TBS). The primary antibody 
diluted in blocking buffer was applied overnight at 4°C with constant gentle shaking. 
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After three times ten min. washes in TBST (0.05 % Tween-20 in TBS), HRP-conjugated 
secondary antibodies were applied for at least 1 hr in blocking buffer, followed by 
three times ten min. washes with TBST. The membranes were washed once with TBS 
before being exposed using the Enhanced Chemiluminescence Detection kit 
(PerkinElmer) according to the manufacturer’s instructions (Western Lightning™, 
Western Blot Chemiluminescence Reagent Plus, PerkinElmer Life Sciences, Inc.). ECL 
photographic film (Hyperfilm™, Amersham Biosciences) was used to expose the 
membranes. The time of exposure varied depending on the signal intensity. To reprobe 
the same membrane with a second antibody, the membrane was incubated with 
stripping buffer for 1 hr at 60°C with rigorous shaking. After one wash with TBST, the 
membrane was incubated in blocking buffer for 30 min before probing with the second 
primary antibody. 
5.2.15 Histology and immunohistochemistry 
5.2.15.1 Perfusion and fixation of mouse tissue 
The mice were deeply anaesthetized by injecting 2.5 % avertin (0.017 ml per g of 
mouse body weight) intraperitoneally. After anaesthesia, the mice were washed with 
70 % ethanol in the stomach and the skin was removed from the ventral side. A 
transversal cut was made just below the diaphragm and the abdomen were slowly 
opened until the heart was visible. A new needle (27 gage) was inserted into the left 
ventricle and, immediately after starting the perfusion, a small incision was made in 
the right auricle to allow the blood to flow out of the body. Perfusion was carried out 
with HBSS and changed from HBBS to fixative (4 % PFA in PB for paraffin embedded 
tissue. The perfusion was carried out with 30-50 ml of fixation solution. The brain and 
the spinal cord were removed carefully and collected into vials with cold perfusion 
buffer. The tissue samples were stored in 4 % PFA overnight at 4°C and then in 1 % 
PFA until further use. 
5.2.15.2 Paraplast impregnation and embedding of the tissue 
After post-fixation, the tissue was washed 3-4 times with PBS. The brains were cut into 
halfes and were transferred into plastic chambers for dehydration and paraplast 
impregnation. The following steps were carried out before tissue embedding: 50 % 
ethanol for 1 hr, twice in 70 % ethanol for 2 hrs, twice in 96 % ethanol for 1 hr and 
twice in 100 % ethanol for 1 hr each. Then, the 100 % ethanol was replaced by 
isopropanol for 1 hr, twice in xylene for 2 hrs and the tissues were impregnated with 
paraplast at 60ºC for 2 hrs. Finally, the tissue was embedded in molten paraplast and 
left to harden. 
5.2.15.3 Haematoxylin-Eosin (HE) staining 
5-7 μm thick sections were cut from the paraffinized block using a microtome. The 
sections were floated on a warm water bath (42°C), placed on positively charged glass 
slides and then dried overnight at 37°C. The sections were then incubated at 60°C for 
10 min before being deparaffinized and rehydrated in the following steps: twice in xylol 
and once in xylol/isopropanol (1:1) for 10 min, 100 %- 90 %- 70 %- 50 % alcohol for 
5 min and finally dH2O. The sections were incubated with 0.1 % haematoxylin for 5 
min staining the basic cell nuclear compartment blue. Following a wash with dH2O, the 
sections were dipped in HCl-alcohol solution once for 5-10 sec and then in Scott’s 
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solution for 5 min. They were briefly rinsed with dH2O, counterstained with 0.1 % 
eosin for 3-5 min and then rinsed with dH2O. Sections were dehydrated by incubating 
them in an increasing alcohol concentration (50 %, 70 %, 90 %, and 100 %) for 2 
min, then in xylol/isopropanol (1:1) and twice in xylol for 5 min. Finally, they were 
mounted with ‘Eukitt’ (Kindler GmbH). 
5.2.15.4 DAB-based immunodetection on paraffin sections 
The sections were processed as described in section 5.2.15.1 until rehydration. The 
sections were then incubated for 5 min in citrate buffer before being ‘cooked’ for 10 
min in boiling citrate buffer (at 650 watts in microwave oven). After this, the sections 
were left in the citrate buffer for about 20 min to cool down and subsequently rinsed in 
Tris buffer/ 2 % milk for 5 min. Endogenous peroxidases were inactivated by 
incubating the sections with 100 μl of 3 % hydrogen peroxide for 5 min. Next, the 
sections were incubated with 100 μl of goat-serum diluted in PBS/BSA (1:5) for 20 min 
at room temperature before proceeding with the 100 μl of the primary antibody diluted 
in PBS/BSA. After an overnight incubation at 4°C, the sections were washed with Tris 
buffer/ 2 % milk and incubated with 100 μl of bridging antibody, i.e. biotinylated 
secondary antibody (Dako) for 10 min. They were then rinsed with Tris buffer/ 2 % 
milk and probed with 100 μl of tertiary complex, i.e. Horseradish Peroxidase 
streptavidin complex (Dako), by incubating the sections for 10 min. They were then 
rinsed with the Tris buffer and incubated with 100 μl of DAB for 10 min. Finally, the 
sections were rinsed twice with dH2O for 5 min each and counterstained for 30 sec 
with haematoxylin following the steps until mounting (section 5.2.15.3). The enzymatic 
reaction between the HRP and DAB yielded a very a stable brown precipitate that was 
visualized under the microscope (section 5.2.15.5) 
5.2.15.5 Light and Fluorescent Microscopy 
The light and fluorescent microscopic observation was performed with an oil immersion 
100x, 63x and 40x lenses and air 20x lenses (Leica, DMRXA) in the different 
experiments and the microscope was equipped with a ProgResC14 camera system 
(Jenoptic, Jena, Germany). The images were digitalized, analyzed and processed using 
Image J software (http://rsbweb.nih.gov/ij) and Photoshop creative suite 3 (Adope). 
5.2.15.6 Image analysis and counting software 
Aquisition of immunostainings were digitalized using a 20x Nikon objective integrated 
in the Veritas microdissection instrument. Veritas operating software automatically 
composes overview images of the region of interest resulting in high resolution image 
composites, which we used for cell quantification. For DAB and thionin stained sections 
we used bright field for image acquisition and in the case of EYFPnuc positive cell 
counting we took advantage of the fluorescence mode using the EGFP filter set of 
Veritas (exitation 503–548 nm, emission 565–585 nm). Composite images were 
processed using a in-house programmed macro in ImageJ, which is a open source 
image processing and analysis tool programmed in Java (http://rsweb.nih.gov/ij/).
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6.1 Exon-level expression profiling of different glial 
populations 
6.1.1 Purification of different glial cell types in the central 
nervous system 
6.1.1.1 FACS sorting of hGFAP-EGFP+ glial precursor cells 
To purify glial precursor cells (GPCs), we took advantage of a transgenic line of 
mice that expresses EGFP driven by the human glial fibrillary acidic protein 
(hGFAP) promoter (Nolte et al., 2001), a well-established glial cell marker. We 
employed FACS to enrich the EGFP+ cells to 99% purity. We purified cortical 
hGFAP-EGFP+ cells at P6 where hGFAP-driven EGFP expression labels two 
populations of astrolgia (i) protoplasmic mature astrocytes and (ii) glial 
precursor cells (GPCs). Therefore a heterogeneous cell population is labeled 
with EGFP at P6, comprising differentiating glial progenitor cells in distinct 
stages including mature astrocytes, as shown in Fig. 5 A, A'. 
6.1.1.2 FACS sorting of Cx3cr1-EGFP+ microglia 
MG were purified through the use of a knock-in mouse line where EGFP was 
placed via homologous recombination in the Cx3cr1 locus (Jung et al., 2000). 
Thus EGFP expression is under transcriptional control of the endogenous Cx3cr1 
promoter a well-established microglia cell marker  (Fig. 5 B, B’). We FACS-
purified the EGFP+ MG at P10 from cortex to yield >99% pure MG. The high 
purity of MG was confirmed by examining the expression levels of genes, which 
are exclusively expressed in MG samples. Our results confirmed the presence of 
well-established MG markers, which are shown in Fig. 7 C.  
6.1.1.3 FACS sorting of Plp1-EGFP+ oligodendrocytes 
To purify oligodendrocytes (OLs) we took advantage of a transgenic mouse line 
that expresses DsRed under control of the Plp1 promoter, which labels 
oligodendrocytes (P.G. Hirrlinger et al., 2005) (Fig. 5 C, C’). We subjected 
cortical cells of these mice at P16 to FACS to yield >99% pure OLs. The high 
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purity of OL was confirmed by examining the expression levels of genes, which 
are exclusively expressed in OL and also include published OL markers Fig. 7 C. 
 
Fig. 5: Transgenic mouse tools for cell type identification and purification via FACS  
Cell type-specific expression of fluorescent proteins in the brain of transgenic mice. (A) 
hGFAP-driven expression of EGFP highlights glial precursor cells (GPC) at P6 in cortex. 
The labeled cell population is highly heterogeneous including early (asterisk) and late 
(arrowhead) precursor cells as well as mature protoplasmic astrocytes (arrow; scale bar = 
50µm). (A’) Typical arborization of mature astrocytes (scale bar = 10µm). (B) The 
Cx3cr1 promoter induces strong expression of EGFP in the major MG cell population in 
cortex at P10 (scale bar = 50µm). (B’) Typical non-activated MG (scale bar = 10µm). (C) 
DsRed expression, driven by the Plp1 promoter stains somata of OLs (P16; scale bar = 
50µm). (C’) Punctate staining in oligodendroglia processes due to clustering effects of 
DsRed in compacted myelin (scale bar = 10µm). 
6.1.2 Microarray quality controls 
Total RNA prepared from purified cell types was used to generate labeled cDNA 
with a one-step linear random-primed amplification protocol to amplify all RNAs. 
This labeled cDNA was hybridized to Affymetrix Mouse Exon 1.0 ST Arrays. We 
performed data analyses using the exonmap package (Okoniewski et al., 2007) 
and Partek Genomic Suite. Fig. 6 depicts a summary of quality controls (QC) of 
the microarray performance. To exclude an overall shift in signal intensities, we 
checked signal distribution by using a histogram as well as box plots serving as 
indicators for general shifts in hybridization performance (Fig. 6 A, B). 
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Unsupervised hierarchical clustering using all data points revealed small, but 
evident differences between GPCs and oligodendrocytes as well as higher 
differences of OL and GPCs to MG (Fig. 2 C). These finding were further 
supported by principal component analysis (PCA) which illustrates the principal 
components of all 7 samples from the surveyed cell types. PCA showed that 
replicate samples group together and different cell types are clearly separated 
from each other, with a distinct separation of MG samples from OL and GPCs 
(Fig. 6 D). 
 
Fig. 6: Quality control parameters of microarray data from purified glial cell types 
(A) Signal distribution of raw microarray data before normalization, depicted as 
histogram (signal intensity on the x-axis, frequency on the y-axis). (B) Box plots of 
normalized data from all microarrays (normalized by Robust Multichip Average (RMA) 
method) show a homogenous intensity distribution. (C) Hierarchical clustering of 
microarray data derived from highly purified CNS cell types revealed three distinct 
clusters representing GPCs, MG, and OLs. The similarity of gene expression between 
different samples is represented by horizontal distances on each branch of the 
dendrogram. Biological replicates show the highest degree of correlation, represented by 
short horizontal distances. (D) Principal component analysis (PCA) revealed high 
correlation of biological replicates and a closer relation of OL to GPCs.  
Considering the highly specialized functions of MG and OLs, the differences in 
their gene expression profiles were anticipated underscoring the different 
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developmental origin of each cell type. However, it is not known how 
expression profiles of GPCs relate to expression profiles of mature OLs or MG. 
6.1.3 Cell type specific expressed genes 
To assess cellular identity of sorted cell types, we identified genes which were 
exclusively expressed in each cell type. We thus applied stringent filter criteria 
to our microarray data and identified genes expressed in a cell type-specific 
fashion as illustrated in Fig. 7 A. Examination of top ranking genes exclusively 
expressed in hGFAP-EGFP+ cells showed an enrichment of genes previously 
shown to be expressed in glial precursor cells such as radial-glia, Ng2+, 
oligodendrocyte progenitor cells (OPCs) and astrocytes (AG). GPC marker genes 
included Tenascin-C (Tnc) (S. Bartsch et al., 1992; Yuasa, 2001) and platelet 
derived growth factor receptor, alpha polypeptide (Pdgfra) (Fig. 7 B). Genes 
exclusively expressed in Cx3cr1-EGFP+ cells showed high enrichment in known 
markers for MG shown in Fig. 7 such as chemokine (C-C motif) ligand 3 (Ccl3), 
complement component 3a receptor 1 (C3ar1) (C.B. Martin et al., 2007), 
prostaglandin D2 synthase 2, hematopoietic (Ptgds2) (Mohri et al., 2007), 
colony stimulating factor 1 receptor (Csf1r) (Pollard, 1997). Top ranked genes 
for Plp1-DsRed+ cells included various marker genes specific for 
oligodendrocytes: myelin-associated oligodendrocyte basic protein (Mobp), 
myelin oligodendrocyte glycoprotein (Mog) (Y. Yamamoto et al., 1994), myelin 
and lymphocyte protein (Mal) and extracellular lysophospholipase D (Enpp2) 
(Cahoy et al., 2008) illustrated in Fig. 7 D. Our unsupervised expression 
analysis thus was able to detect known and well-described marker genes for 
each examined cell type. Furthermore, could we detect several genes, which 
were not previously published as exclusively expressed in the cell types under 
investigation. 
RESULTS 
 50
 
Fig. 7: Genes strongly enriched in isolated cell types.  
(A) Heatmap of 158 genes which showed highly significant exclusive expression in the 
cell types indicated. Selection criteria for hGFAP-EGFP+ cells: one-way ANOVA FDR < 
0,01 and fold change > 7, resulting in 30 genes; for Cx3cr1-EGFP+ cells: one-way 
ANOVA FDR < 0,0001 and fold change > 10, resulting in 88 genes; and for Plp1-DsRed+ 
cells: one-way ANOVA FDR < 0,01 and fold change > 8, resulting in 40 genes. 
Expression levels of top ranking genes, which showed high enrichment in hGFAP-EGFP+ 
cells (B), in Cx3cr1-EGFP+ cells (C), and in Plp-DsRed+ cells (D). The y-axis represents 
normalized intensities determined by RMA normalization. Error bars represent standard 
deviation (SD).  
6.1.4 Classification of FACS-purified cell populations based on 
marker gene expression 
To further classify the identity of cells, which were positive for EGFP under 
transcriptional control of the hGFAP promoter at P6, we looked for mRNA 
expression levels of published cell type-specific marker genes. Known marker 
genes for GPCs such as Pdgfra , Gfap, and epidermal growth factor receptor 
(Egfr), revealed robust expression in GPCs (Fig. 4 A). Interestingly, we found 
markers such as chondroitin sulfate proteoglycan 4 (Cspg4/Ng2) and SRY-box 
containing gene 10 (Sox10) as being expressed at very low levels in GPCs. 
Astroglial and glial precursor markers were not detected in MG samples, 
whereas OL data revealed low expression of all markers (Fig. 8 A). Transcript 
data for selected glutamate transporters Glast and Glt-1 show significant 
expression in GPCs and OLs, but not in MG, similar to the AMPA receptor 
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subunit Gria2 (Fig. 8 B). We detected a very low expression of glutamate 
receptor, ionotropic, NMDA1 (Grin1) exclusively in OL. Unexpectedly, we 
identified several neuronal markers expressed in GPCs and OL, including neural 
cell adhesion molecule 1 (Ncam1), doublecortin (Dcx), and neurofilament, 
medium polypeptide (Nefm) (Fig. 8 C). Expression of additional neuronal 
marker genes such as cholinergic receptor, nicotinic, alpha polypeptide 3 
(Chrna3), enolase 2 (Eno2), neural PAS domain protein 1 (Npas1), and 
cholinergic receptor, nicotinic, alpha polypeptide 5 (Chrna5) (Cahoy et al., 
2008), was virtually absent in all samples.  
 
Fig. 8: Classification of FACS-purified cell populations based on marker gene 
expression. 
Expression levels of marker genes in FACS-purified cell populations for (A) glial 
precursors, (B) Glutamate transporters/receptors, and (C) neurons . The y-axis represents 
the level of normalized gene expression. Error bars represent SD; n = 2 (GPC, OL) and n 
= 3 (MG). 
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6.1.5 Cell type-specific alternative splicing events 
To estimate the degree of alternative splicing events that occur in GPCs, OLs 
and MG, the data was subjected to exon level analysis. A one-way ANOVA test 
was applied to identify cell type-specific alternative splicing events. The exon 
level analysis was performed using the exonmap package in R (Okoniewski et 
al., 2007). Out of > 28,000 genes we identified 2478 transcripts supported by 
microarray data as being alternatively spliced between different cell types, with 
significant p-values in the one-way ANOVA test (p-val < 0.0001). In Table 2 are 
the top ranking 50 genes listed (genes ranked according to their ANOVA p-
value). 
Table 2: Putative cell type specific alternative spliced genes 
Symbol Description  Symbol Description 
Ryr2  ryanodine receptor 2, cardiac   Inpp5d  inositol polyphosphate-5-phosphatase D  
Stab1  stabilin 1   Atp13a4  ATPase type 13A4  
Lrp1b  low density lipoprotein-related protein 1B  Arhgap9  Rho GTPase activating protein 9  
Bcan  brevican   Npr2  natriuretic peptide receptor 2  
Cspg5  chondroitin sulfate proteoglycan 5   Ntrk3  neurotrophic tyrosine kinase, receptor, type 3  
Grin2c  glutamate receptor, ionotropic, NMDA2C (epsilon 3)   Syne1  synaptic nuclear envelope 1  
Acsl6  acyl-CoA synthetase long-chain family member 6   Nwd1  NACHT and WD repeat domain containing 1  
Plcb4  phospholipase C, beta 4   Myo1f   myosin IF  
Fusip1  FUS interacting protein (serine-arginine rich) 1  Fgfr3  fibroblast growth factor receptor 3  
Itgam  integrin alpha M   Synj2  synaptojanin 2  
Pfkm phosphofructokinase-1  Ttll11 tubulin tyrosine ligase-like 1 
Dtna  dystrobrevin alpha   Col2a1  collagen, type II, alpha 1  
Fgfr2  fibroblast growth factor receptor 2   Vegfa  vascular endothelial growth factor A  
Dmd  dystrophin, muscular dystrophy   Gsn  gelsolin  
Jarid1d  jumonji, AT rich interactive domain 1D (Rbp2 like)   Pde3b  phosphodiesterase 3B, cGMP-inhibited  
Ptpro  protein tyrosine phosphatase, receptor type, O   Atp2b3  ATPase, Ca++ transporting, plasma membrane 3  
Dock3  dedicator of cyto-kinesis 3   Ptprc  protein tyrosine phosphatase, receptor type, C  
Myo10 Myosin 10 Plat plasminogen activator, tissue  
Mlxipl  MLX interacting protein-like   Bai1  brain-specific angiogenesis inhibitor 1  
Sytl2  synaptotagmin-like 2   Atp1a2  ATPase, Na+/K+ transporting, alpha 2 polypeptide  
Dnm1  dynamin 1   Acsbg1  acyl-CoA synthetase bubblegum family member 1  
Sgk1  serum glucocorticoid regulated kinase 1   Polr3h polymerase (RNA) III (DNA directed) polypeptide H 
Ltbp1  latent transforming growth factor binding protein 1   Tmem87a  transmembrane protein 87A  
Egr1  early growth response 1   Dgkb  diacylglycerol kinase, beta  
Mlc1  megalencephalic leukoencephalopathy   Abca9  ATP-binding cassette, sub-family A (ABC1), 9  
Ptprt   protein tyrosine phosphatase, receptor type, T   Myo7a  myosin VIIa  
Ngef  neuronal guanine nucleotide exchange factor   Pcdha4  protocadherin alpha 4  
 
Five examples for genes that show significant evidence for alternative splicing 
were chosen for detailed illustration in Fig. 9 and Fig. 10. Exon level expression 
profiles of plasminogen activator, tissue (Plat), which is a serine protease 
involved in extracellular metabolism (Endo et al., 1999), as one of the 
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candidates is depicted in Fig. 9 A. Profiles show high expression of Plat in OLs 
and GPCs in most of the probesets except for a region spanning four exons 
where we observed a much lower expression (indicated by a black circle). Fig. 9 
B depicts the expression profile of phosphofructokinase-1 (Pfkm), one of the 
key enzymes that catalyze glycolysis. Transcripts of Pfkm exhibit cell type 
specific isoforms, which are not annotated in Ensembl (Fig. 9 B). Another 
interesting candidate is Myosin 10 (Myo10), of which 4 isoforms are annotated 
in Ensembl. In the CNS, both full-length Myo10 and a shorter form of Myo10 
that lacks a myosin head domain, are expressed. The 'headless' Myo10 variant 
is unable to function as a molecular motor, but is otherwise identical to the full-
length transcript. All isoforms are expressed in neurons, such as Purkinje cells, 
as well as non-neuronal cells, such as astrocytes and ependymal cells (Sousa et 
al., 2006). Expression profiles indicate a higher expression level of the short 
isoforms in GPCs (Fig. 9 C). Expression profiles for full-length Myo10 revealed 
several exons, which are potentially alternatively spliced between different cell 
types. 
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Fig. 9: Cell type-specific alternative splicing events.  
Expression levels in each of the exon probesets across the entire length of transcripts 
from different cell types under investigation are shown. Blue profiles represent the mean 
signal intensity in the three replicates of microglia (MG) samples, green profiles plot the 
mean signal intensity in the two arrays derived from glial precursors cells (GPC), and the 
orange graphs depict the mean signal intensity in the two arrays probed with 
oligodendroglial (OL) samples. Ensembl-annotated splice variants of each gene are 
illustrated in the upper panels. Exonic regions are illustrated as grey bars in the lower 
panels. Black circles indicate hot spots for putative alternative splicing events. '>' or '<' 
(next to gene name) indicates direction of transcription. (A) Plasminogen activator, tissue 
(Plat) is potentially alternatively spliced in GPC and OL and not expressed in MG. (B) 
Phosphofructokinase-1 (Pfkm) expression profiles show high levels for OL and GPC, 
which deviate in exons located in the middle of the gene. (C) Expression profiles of 
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Myosin 10 (Myo10), for which 4 transcripts are annotated in Ensembl, show specific 
expression of short variants in GPC. Additional splice variants are detected in exons 
coding for the full-length version (right circle).   
Expression profiles of tubulin tyrosine ligase-like 1 (Ttll1), which catalyzes the 
addition of tyrosine to the C-terminal glutamate of α-tubulin, exhibit high 
correlation between GPC and OL, in contrast to MG (Fig. 10 A). Some exons in 
the MG samples show very low expression in comparison to OL and GPC 
samples. As an example for potential exon skipping, we found polymerase 
(RNA) III (DNA directed) polypeptide H (Polr3h) shown in Fig. 10 B. Exon three 
shows high expression only in GPC samples, whereas its expression dropped to 
background levels in MG and OL.  
 
Fig. 10: Putative cell type-specific exon skipping events 
Expression levels in each of the exon probesets across the entire length of transcripts 
from different cell types under investigation are shown. Blue profiles represent the mean 
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signal intensity in the three replicates of microglia (MG) samples, green profiles plot the 
mean signal intensity in the two arrays derived from glial precursors cells (GPC), and the 
orange graphs depict the mean signal intensity in the two arrays probed with 
oligodendroglial (OL) samples. Ensembl-annotated splice variants of each gene are 
illustrated in the upper panels. Exonic regions are illustrated as grey bars in lower panels. 
Black circles indicate hot spots for putative alternative splicing events. '>' or '<' (next to 
gene name) indicates direction of transcription. (A) Tubulin tyrosine ligase-like 1 (Ttll1) 
exhibited significant lower expression for three adjacent exons in MG samples. (B) 
Polymerase (RNA) III (DNA directed) polypeptide H (Polr3h) shows closely related 
expression profiles for all cell types under investigation, except for exon three which is 
exclusively expressed by GPC.  
Genes which are down regulated in mutants may reflect disease relevant pathways 
which are shut . They are probably involved in oligodenglial axonal support and could 
therefore serve as surrogate marker for potential drug targets 
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6.2 Transcriptional and histological analysis of specific 
neurons and white matter tracts in Cnp1 and Plp1 
deficient mice over time  
Previous studies have shown that the myelin protein composition as well as its 
ultra-structure is not dramatically changed in mice lacking CNP and PLP 
(Klugmann et al., 1997; Lappe-Siefke et al., 2003). Although oligodendrocytes 
are depleted of highly abundant myelin proteins, Cnp1  and Plp1 null mice 
exhibit no sign of dysmyelination, and show no obvious developmental delay. 
However, myelinated neurons of Cnp1 as well as Plp1 null mutant mice develop 
axonal swellings, leading to axonal degeneration in the mature animal. The 
underlying molecular mechanism of which has not been identified so far. We 
speculate that oligodendrocytes not only ensheathe axons for the purpose of 
saltatory nerve conduction, but also provide trophic support to the axon. Thus 
far, the nature of this glial support function is poorly understood. To 
characterize the impact on cellular composition in the brain caused directly or 
indirectly by loss of Cnp1 and Plp1, we studied the inflammatory responses as 
well as overall glial and neuronal cell numbers. We aimed to characterize the 
response of several cell types in the motor cortex as well as in the 
corresponding white matter tracts at different time points during progression of 
the phenotype. For our analyses we chose animals of 1, 3, 6, and 12 months of 
age. Per time point we used three, sex (male) and age matched, biological 
replicates. Sample from each time point were subjected to 
immunohistochemical (IHC) staining, RNA expression analysis and biochemical 
experiments to validate and correlate our findings with different methods.  
6.2.1 Consequences of Cnp1 and Plp1 deficiency on cellular 
composition in primary motor cortex and corpus callosum 
Due to the exclusive expression of Cnp1 and Plp1 in OL we examined whether 
the overall number of OLs is altered over time in the respective null mutant 
mice. We took advantage of cell type specific marker protein expression to 
quantify cell type abundance. First, we quantified the overall number of 
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oligodendrocytes in primary motor cortex (Cx) and white matter tracts of the 
corpus callosum (WM) at 1, 3, 6, and 12 months of age. An anti-CC1 antibody 
raised against the adenomatous polyposis coli (APC) protein, which is a well-
characterized marker for oligodendrocytes, was used for labeling and 
subsequent quantification (Bhat et al., 1996), see Fig. 11 A, B. Quantification of 
CC1+ cell bodies revealed no significant difference in oligodendrocyte numbers 
between wild-type (WT), Cnp1 and Plp1 mutants in Cx and in WM, as shown in 
Fig. 11 B. Due to unspecific binding of CC1 antibody at least on paraffin 
sections of aged mouse brains, we could not reliably quantify CC1 IHC stainings 
of 12 months old animals (Fig. 11 A, B, right panel). Based on our data we 
conclude that the number of oligodendrocytes remains unchanged until the age 
of 6 months.  
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Fig. 11: Cnp1 and Plp1 mutant mice reveal no change in oligodendrocyte number  in 
WM and Cx. 
(A) Representative photomicrographs of CC1 IHC in mouse brain. Brains from all time 
points were post-fixed in 4% PFA, and near-midsagittal sections were subjected to 
immunostaining. Images of CC1 (brown) immunostaining and DAPI (blue) 
counterstaining were captured digitally. Scale bar = 50 µm. (B) Total numbers of CC1+ 
cells in Cx and WM per 0.5 mm2, error bars indicate standard deviation (SD). 
Quantification was done in a semi-automated manner using a self developed ImageJ 
macro, and were based on CC1+ cell bodies. Total numbers of CC1+ cells were 
unchanged over all time points in all genotypes. High values at the 12 months time point 
in Cx are due to unspecific binding of CC1 antibody in aged brains. 
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Previous studies on Cnp1 mutants showed extensive accumulation of amyloid 
precursor protein (APP) in axons of WM appearing at 1 month progressing up 
to 6 months of age. Moreover, the overall number of axons is decreased in WM 
at 6 months old mice (Burzyńska, 2007). These findings prompt the question 
whether neuronal cell bodies in the Cx of Cnp1 mutant mice are also decreased. 
We used the NeuN (Neuronal Nuclei) antibody, which labels most neuronal cell 
types throughout the nervous system of mice (including cerebellum, cerebral 
cortex, hippocampus, thalamus, spinal cord, and neurons in the peripheral 
nervous system including dorsal root ganglia, sympathetic chain ganglia, and 
enteric ganglia). NeuN staining shown in Fig. 12 A exhibit normal distribution 
and morphology of neurons in Cx compared to WT. Quantification showed no 
significant changes in neuronal numbers over time (Fig. 12 B). NeuN+ cell 
bodies were counted within an area of 0,5 mm2 from three sections, derived 
from three animals per genotype at 1, 3, 6, and 12 months of age. 
In addition to the APP+ axonal swellings other well described hallmarks of 
neuronal degeneration such as increased astrogliosis (accumulation of Gfap+ 
astrocytes) and microglyosis (activation and invasion of Iba1+ microglia) were 
found. Immunostaining for ionized Ca2+-binding adaptor 1 (Iba1), which is 
expressed selectively in microglia/macrophages and is a Ca2+-binding peptide 
produced by activated monocytes and microglial cells, is shown in Fig. 13 A. 
Alterations in overall numbers of Iba1+ cells reflect the extend of activation, 
invasion or proliferation of microglia in central nervous system (CNS). 
Quantification of Iba1+ cells shown in Fig. 13 B, revealed a significant increase 
of microglia in WM at several time points in Cnp1 and Plp1 mutants. Microglial 
activation was found to peak at 1 and 12 months of age in Cnp1 mutants and 
at 6 months of age for Plp1 mutants.  
  
RESULTS 
 
 61
 
Fig. 12: Neuronal cell numbers are unchanged in Cx and WM 
(A) Representative photomicrographs of NeuN immunostaining in mouse brain. Brains 
from all time points were post-fixed in 4% PFA, and near-midsagittal sections were 
subjected to immunostaining. Images of NeuN (brown) immunostaining and DAPI (blue) 
counterstaining were captured digitally. Scale bar = 50 µm. (B) NeuN+ cells in Cx and 
WM per 0,5 mm2.The total number of NeuN+ cells was unchanged over all time points in 
all genotypes. 
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Fig. 13: Microglial cell numbers increased in Cx and WM over time in myelin 
mutant mice 
(A) Representative photomicrographs of IBA1 immunostaining in mouse brain. Brains 
from all time points were post-fixed in 4% PFA, and near-midsagittal sections were 
subjected to immunostaining. Images of IBA1 (brown) immunostaining and blue DAPI 
counterstaining were captured digitally. Scale bar = 100 µm. (B) IBA1+ cells in Cx and 
WM per 0,5 mm2. Quantification was done in a semi-automated manner using an in-
house developed ImageJ macro. Total number of IBA1+ cells were increased in WM of 
mutants at all time points. 
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Another histological indication for ongoing inflammatory processes within the 
CNS is reflected by an increase in astrocyte activation, which can be detected 
by α-GFAP IHC. Under control conditions astrocytes were present at low level 
throughout the brain parenchyma, both in WM and Cx. Morphologically, resting 
astrocytes are characterized by numerous thin fibrillary processes, forming a 
net-like pattern. Identification and quantitation of astrocytes is challenging due 
to their great abundance and numerous processes formed by this cell type. In 
addition, classification, as done for MG, of astrocytes was not possible due to 
high intra-region variability of the degree of reactive gliosis. We therefore 
quantified astrogliosis using the area (in percent), which is covered by GFAP 
staining in defined regions within Cx and WM (Fig. 14A). Quantification in WM 
revealed, similar to the results for microglia, an increased staining for GFAP in 
Cnp1 mutants at 1, 3, and 6 months which was finally adapted at 12 months by 
increased staining also in WT and Plp1 mutant mice. Both WT and Plp1 mutant 
samples show a progressive increase in GFAP staining over time (Fig. 14B). Cx 
was not affected at 1 and 3 months by astrogliosis, but dramatically developed 
in Cnp1 mutants at 6 and 12 months of age. Expression patterns for WT and 
Plp1 mutants were very similar at all time points in Cx. 
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Fig. 14: Increased activation and invasion of GFAP+ astrocytes in Cx and WM in 
myelin mutants over time 
(A) Representative photomicrographs of GFAP immunostaining in mouse brain. Brains 
from all time points were post-fixed in 4% PFA, and near-midsagittal sections were 
subjected to immunostaining. Images of GFAP (brown) immunostaining and DAPI (blue) 
counterstaining were captured digitally. Scale bar = 100 µm. (B) Percentage of GFAP 
signal in Cx and WM. Quantification was done in a semi-automated manner using an in-
house developed ImageJ macro. There is more GFAP signal detected in Cx of Cnp null 
mice at 6 months and 12 months of age, in WM more GFAP is observed at 1, 3, and 6 
months of age compared to WT controls. 
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In summary, oligodendrocytes appear normal in morphology and number in Cx 
and WM. Similar results were obtained for NeuN staining, which labels neurons. 
Hallmarks of microgliosis as well as astrogliosis were present for Cnp1 and Plp1 
mutant mice. WM regions were more severely affected than Cx. Cnp1 mice 
furthermore showed an earlier and more severe progression of astro- and 
microgliosis compared to Plp1 mutant mice, which is in agreement with 
previously published data (Klugmann et al., 1997; Lappe-Siefke et al., 2003). 
Table 3: Summary of histological observations in WM and Cx of WT controls, Cnp1-
/- and Plp1-/Y 
  1M 3M 6M 12M 
  Cx WM Cx WM Cx WM Cx WM 
WT - - - - - - 
Cnp1-/- - - - - - - CC1 
Plp1-/Y - - - - - - 
NA 
WT - - - - - - - - 
Cnp1-/- - - - - - - - + NeuN 
Plp1-/Y - - - - - - - + 
WT - - - - - - - - 
Cnp1-/- + + - + - ++ +++ ++ IBA1 
Plp1-/Y - + - + + ++ - + 
WT - - + + - + - ++ 
Cnp1-/- + ++ + ++ +++ ++ ++ ++ GFAP 
Plp1-/Y + + + + - ++ - ++ 
6.2.2 Impact of the loss of Cnp1 on distinct neuronal cell type 
populations 
Previous observations from a pilot study, where we isolated cerebellar Purkinje 
cells (PC) employing laser capture microdissection, indicated a substantial loss 
of PC in Cnp1 mutant mice. This is in contrast to the results of NeuN staining in 
cerbral cortex, where we could not verify this finding for cortical neurons. It is 
possible that only a specific group of cortical neurons is affected by the loss of 
Cnp1, which could be masked by quantifying all neurons. We therefore 
subjected callosal projection neurons in the Cx of TYNC mice to a more detailed 
histological analysis. This particular mouse line expresses a nuclear variant of 
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EYFP (EYFPnuc) under transcriptional control of the Thy1 promoter (Rossner et 
al., 2006) predominantly in CPNs. To examine the impact of Cnp1 and Plp1 loss 
on neuronal survival, we compared total number of CPN and PC present at 3 
months and 12 months of age in the Cnp null mutant mice versus WT controls. 
For quantification of cerebellar PC we used a thionine staining, which labels cell 
bodies (Fig. 15 A). PC were identified based on their characteristic location, 
morphology and size (Fig. 15 B). We counted the total number of PC in lobe 
five and six in three animals per genotype, by quantifying 10 sections per 
animal in 3 and 12 months old mice. Analysis revealed no significant difference 
at 3 months but a significant reduction to 25% of WT levels in Cnp1 mutants at 
12 months (Pval < 0.001, students T-test), illustrated in Fig. 15 C. For 
quantification of EYFPnuc+ CPN we took 8µm coronal cryosections (Fig. 15 E) of 
three animals per genotype and analyzed ten sections per animal. 
Quantification was performed with an automated cell recognition ImageJ 
macro, which detects EYFPnuc+ cells in a predefined cortical region (Fig. 15 D). 
Analysis revealed no significant difference between WT and Cnp1-/- at 3 and 12 
months of age shown in Fig. 15 E. 
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Fig. 15: Lack of Cnp1 causes substantial loss of Purkine cells 
Histological analysis of the cerebellar and cerebral cortex of wild-type and Cnp1 null 
mutant mice. (A) Sagital cryosection of wild-type (WT) cerebellum stained with thionine; 
scale bar = 500 µm. The inset represents the region of images shown in higher 
magnification (B). The left panel shows cerebellar cortical sections with an intact 
Purkinje cell layer of 3 to 12 months old WT mice; scale bar = 50µm. Cnp1 mutant mice 
show progressive Purkinje cell loss from 3 to 12 months. (C) Average number of Purkinje 
cells per lobes 5+6 at 3 and 12 months of age. (D) Coronal cryosection of cerebral cortex 
of wild-type and Cnp1  mutant mice. CPN express transgenic EYFPnuc in motor and 
somatosensory cortex, scale bar = 50 µm. (E) Quantification of total EYFPnuc+ cells in 
wild-type and Cnp1 mutant mice shows no significant change in 12 months old mice. 
Values are relative to wild-type levels in percent. 
6.2.3 Isolation of CPN and WM by LCM 
Applying high throughput techniques like DNA microarrays in the CNS is still 
challenging due to the presence of multiple different cell types. In order to get 
reliable and reproducible results it is mandatory to reduce the cellular 
complexity as much as possible, and to perform the analysis with a defined cell 
population. The use of LCM has proven especially helpful in isolating specific 
neuronal population from Cx (Rossner et al, 2006).  
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We used 8µm coronal cryosections for single cell isolation. Coronal cryosections 
were prepared from primary medial motor cortex (bregma +1 to +0.5, Fig. 16 
A). EYFPnuc-expressing CPN were identified using the fluorescence mode of the 
Veritas microdissection instrument (Molecular Devices), shown in Fig. 16 B. 
EYFP+ CPN were collected from primary motor cortex and the somatosensory 
cortex (target area highlighted in yellow). Single CPN are depicted in Fig. 16 
prior to LCM (C), following LCM (D) and isolated on the capture cap (E). We 
collected 600 -700 CPN for each animal. One aim of our study was to generate 
gene expression profiles of neurons, which are deprived of oligodendroglial 
support. In this context it is also of interest as to know, how OLs react upon 
loss of Cnp1 or Plp1 on the level of transcription. Isolation of OLs in adult CNS 
was at least for us impossible because of lack of proper mouse tools, which 
allow LCM-compatible OL identification. Additionally are cellular dimensions of 
oligodendrocytes below the size threshold of our microdissection device.  
However, to obtain expression profiles of adult oligodenrocytes, we decided to 
isolate the corpus callosum, a WM region enriched for oligodendrocytes. WM 
micro-regions were isolated from the same coronal plane depicted in green box 
in Fig. 16 A. Fig. 16 F-H shows the corresponding procedure for WM before and 
after LCM, and the captured area on the cap. WM micro-regions were isolated 
from 15 cryosections (20 µm thick), which were previously mounted on PEN 
membrane-framed slides. For single cell isolation we employed the capture 
modus using only IR laser to attach neurons to the capture cap. Micro-regions 
were isolated using the UV laser (UV-power set to 4 mW), attachment to the 
cap was done with the IR laser (power = 75 %; pulseduration = 2000 - 5000 
µsec). Immediately after LCM, single cells and micro-regions were lysed in RLT 
buffer (Qiagen). Total RNA amounts derived from LCM samples were in the 
range of 500 pg for CPN and 1-5 ng for WM micro-regions per sample. RNA 
integrity could not be evaluated since the RNA yield was below the detection 
limit. RNA was subjected to a T7-based two-round amplification protocol prior 
to microarray hybridization. RNA amplification yielded between 11.2 - 22.4 µg 
for CPN and 31.3 - 45.3 µg for WM samples. The fragment size of amplified 
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RNA was determined by electrophoretic separation on an Agilent RNA Bio-Lab-
chip, shown in Fig. 16 I. Antisense RNA abundance (fluorescence) is graphed as 
a function of RNA fragment size. The mRNA profiles demonstrate a significant 
population of fragments in the 200-1,200 nt size range and serves therefore as 
a measure of successful amplification. 
 
Fig. 16: Fluorescence-directed laser microdissection enables the isolation of RNA 
derived from neuronal cell types with high precision. 
(A) Anatomical structure of the coronal mouse brain (adapted from Paxinos mouse brain 
atlas (Paxinos and Franklin, 2004)). The black rectangular represents the area of 
fluorescent micrograph for single cell isolation (mirrored in (B)); the green box represents 
the area for WM micro-region isolation (F-H). (B) Fluorescent micrograph was taken 
from a 6 months old WT brain. For better orientation, the boundaries of the corpus 
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callosum (WM) and of the lateral ventricle (LV) were marked in the fluorescent picture. 
In Cx, at the level of the primary motor and somatosensory areas, mainly cells of the 
deeper layers are EYFPnuc+ (layer V and few cells in layer VI). In the upper layers II, 
III, and IV, a low number of dispersed cells were EYFPnuc positive, usually with a 
weaker signal intensity. Samples isolated with laser microdissection were chosen from 
the primary motor and somatosensory cortex (yellow area); 20x magnification; scale bar 
= 200 µm. (C-E) Fluorescence-directed laser microdissection of single EYFPnuc+ CPN. 
In the fluorescent mode, single cells were identified and attached via Laser Capture to a 
HS capture cap; only strongly EYFPnuc-expressing cells in the plane of section were 
chosen for isolation. The infrared (IR) laser settings were chosen to cover the nucleus as 
precisely as possible using a 60x objective. Cells with other nuclei in close proximity 
were not isolated. Depicted are five nuclei (arrows) at a distance where contamination 
was considered to be low. Successful capture was controlled in the bright field and 
fluorescent mode on the tissue section (D) and on the HS cap (E); 60x magnification; 
scale bar = 20 µm. (F-H) LCM of WM micro-regions was performed on 20 µm thionine-
stained adjacent cryosections, which were mounted on PEN membrane slides. (F) Section 
prior to LCM; (G) section post LCM; (H) cap after LCM. LCM was performed with a 
combination of laser capture and UV-directed microdissection. WM was collected from 
12 sections; 20x magnification; scale bar = 100 µm. (I) Aliquots of each amplified RNA 
were separated by capillary electrophoresis (Agilent Bioanalyzer, together with the RNA 
6000 Series II Nano Kit), along with RNA ladder (L; Ambion). Shown are aRNAs after 
two rounds of linear amplification from all samples derived from the 3 months time point.  
6.2.4 Microarray quality controls 
Our approach to restrict cellular complexity using LCM comprises a major 
experimental challenge. LCM on brain samples is a technically highly demanding 
method, which is not per se compatible with microarray technology due to 
extremely low RNA yield. We therefore introduced quality controls on several 
levels, addressing the following questions: 
• How large is the variation between samples after 2 round amplification? 
• How preserved is RNA integrity after LCM? 
• Are correlation co efficiencies of biological replicates higher than 
between non replicates? 
Evaluation of microarray performance was assessed via standard microarray 
quality control parameters shown in Fig. 17. Box plots in Fig. 17 A depict signal 
distributions of raw data (upper panel) and normalized data (lower panel) and 
show comparable distributions for all microarrays analyzed in this study. In 
order to exclude factors which may bias the analysis, we evaluated also the 
extend of RNA degradation for each sample. For this purpose we generated a 
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RNA degradation plot seen in Fig. 17 B. All probes are ordered according to 
their relative position in the coding transcript (from 5'- to 3'-end). Arithmetic 
mean intensity for every position results in a specific slope for each microarray, 
which reflects the degree of RNA degradation. The results show similar slopes 
for all microarrays. Thus, we could exclude a bias originating from different 
RNA degradation rates in samples during LCM.  
 
Fig. 17: Quality controls of microarray data obtained with LCM-derived RNA 
(A) Box plots of raw data from all microarrays (upper panel) and after RMA 
normalization (lower panel) show a homogenous intensity distribution. After 
normalization all microarrays have the same signal intensity distribution. (B) RNA 
degradation plot.  Within each probe set, probes are numbered directionally from the 5'- 
to the 3'-end. Probe intensities are averaged by probe number, across all genes. All traces 
show the same slope indicating a similar RNA degradation degree for all samples. (C) 
Representative scatter plots of biological replicates show a high correlation coefficient, 
which was between 0,97 and 0,99 for all replicates.  
Correlation coefficients of biological replicates were within 0.97 and 0.99, 
representative scatter plots of biological replicates are shown in Fig. 17 C. 
Affymetrix quality controls are listed in Table 4 and further support the high 
performance of our LCM-based microarray analysis. In summary, all quality 
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controls met stringent criteria and indicate that our generated microarray data 
is highly consistent between biological replicates, confirming the viability of the 
dataset. 
Table 4: Standard Affymetrix quality control parameters 
Sample Age Back-ground 
Present 
Calls[%] 
WT R1 1M 59 48 
WT R2 1M 78 53 
WT R3 1M 64 40 
Plpy/- R1 1M 70 49 
Plpy/- R2 1M 50 47 
Plpy/- R3 1M 112 45 
Cnp-/- R1 1M 76 50 
Cnp-/- R2 1M 72 49 
Cnp-/- R3 1M 64 50 
WT R1 3M 76 47 
WT R2 3M 59 51 
WT R3 3M 69 46 
Plpy/- R1 3M 78 50 
Plpy/- R2 3M 64 51 
Plpy/- R3 3M 78 50 
Cnp-/- R1 3M 76 52 
Cnp-/- R2 3M 76 51 
Cnp-/- R3 3M 89 53 
WT R1 6M 79 46 
WT R2 6M 75 44 
WT R3 6M 65 47 
Plpy/- R1 6M 65 46 
Plpy/- R2 6M 70 48 
Plpy/- R3 6M 68 47 
Cnp-/- R1 6M 66 48 
Cnp-/- R2 6M 60 48 
Cnp-/- R3 6M 64 46 
WT R1 12M 72 51 
WT R2 12M 78 52 
WT R3 12M 81 52 
Plpy/- R1 12M 80 50 
Plpy/- R2 12M 75 52 
Plpy/- R3 12M 74 52 
Cnp-/- R1 12M 70 51 
Cnp-/- R2 12M 115 45 
Cnp-/- R3 12M 102 51 
6.2.5 Marker gene expression exhibit high cell type specificity 
Gene expression analysis in the CNS is generally complicated by the coexistence 
of many different cell types, resulting in high background noise and the inability 
to detect small differences in cell type specific gene expression. The purification 
of single populations of cortical projection neurons should overcome these 
limitations and allow us to generate expression profiles of defined neuronal 
populations. 
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To assess the degree of purification obtained by our LCM procedure, we first 
assessed the expression of known cell type markers illustrated in Fig. 18. 
Depicted are arithmetic means of normalized intensities derived from three 
biological replicates including standard deviation. In Fig. 18 A we examined the 
expression of Cnp1 and Plp1 in WT vs. null mutants animals, which serves also 
as a direct validation of proper sampling. These genes are only expressed by 
myelinating cells and are therefore well accepted oligodendrocytic markers. 
Transcription levels of Cnp1 and Plp1 were very high in wild-type WM samples 
whereas null mutants showed no signal for their corresponding knock-out gene 
(upper panel). Expression of Cnp1 and Plp1 were 1000 fold decreased in CPN to 
very low signal intensities. 
 The expression of neuronal markers like Enolase 2 (Eno2) or Thymus cell 
antigen 1, theta (Thy1, shown in Fig. 18 B) are absent in WM but show very 
high expression in all CPN samples. Eno2 showed a slight increase of expression 
over time in all genotypes whereas Thy1 expression remained constant over 
time. From the IHC results (Fig. 3 and 4) where we detected higher expression 
of astrocytic and microglial markers especially in WM samples of Cnp1 and Plp1 
mutant mice, we expected that this should be also reflected on the level of 
transcription. Fig. 18 C (left panel) depicts mRNA expression profiles of Gfap, a 
known marker for activated astrocytes. Profiles exhibit a constant low 
expression in WT samples at all time points, whereas in Plp1 and Cnp1 mutants 
the expression increased significant over time starting at 3 months. In the CPN 
samples, Gfap expression could not be detected. To check on the 
transcriptional level whether the overall numbers of astrocytes changed, 
regardless of their physiological status, we evaluated S100b expression (Fig. 18 
C, right panel). In WM samples, we could not detect significant changes of 
S100b expression between genotypes. Unexpectedly, we also observed a robust 
mRNA expression profile of S100b in CPN, exhibiting a similar pattern for all 
genotypes investigated. Gene expression analysis of microglia markers Mac-2 
and Iba1 (Fig. 18 D, upper panel) revealed the same results as for Gfap with 
very weak expression in WT samples and an increasing expression over time in 
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Cnp1 and Plp1 mutant mice in WM. CPN showed no signal for microglial 
markers (Fig. 18 D, lower panel). 
 
Fig. 18: Validation of LCM isolation precision based on cell type specific marker 
gene expression. 
(A) mRNA levels of the oligodendrocyte-specific marker genes Plp1 and Cnp1 are highly 
enriched in WM versus CPN samples in wild-type animals. In mutant animals the mRNA 
signal is completely absent. (B) Neuronal markers Thy1 and Eno2 are highly expressed in 
neuronal samples and show very weak expression in WM samples. (C) Gfap expression 
as a marker for activated astrocytes shows age-dependent up-regulation in Plp1 and Cnp1 
mutant mice, whereas in WT controls Gfap expression stays constant at low levels during 
aging. Gfap signal could not be detected in neuronal samples. S100b, another accepted 
marker for astrocytes, is robustly expressed in CPN as well, and its expression levels do 
not change over time in all studied genotypes. (D) As markers for microglia, Iba1 and 
Mac-2 were used. Iba1 is supposed to stain all microglia and Mac-2 only activated 
microglia. According to the expression data, the number as well as the activation status is 
increased in WM over time in myelin mutants. Bar plots represent arithmetic means (n = 
3), error bars indicate SD. 
6.2.6 Loss of Cnp1 and Plp1 mediates substantial gene expression 
changes in CPN and WM  
Cnp1 and Plp1 knock-out animals develop an axonal pathology albeit these 
proteins are predominantly expressed in oligodendrocytes. It is not known so 
RESULTS 
 
 75
far whether a dysfunction of oligodendrocytes can mediate transcriptional 
changes in myelinated neurons. We identified a significant amount of 
differentially expressed genes in CPN and in WM of Cnp1 and Plp1 mutant mice. 
To identify these genes we performed pair-wise comparisons as well as two-
way ANOVA tests. The analysis revealed a large number of significantly 
differentially expressed genes (adj. p-val. < 0.001, Benjamin Hochberg 
correction), which were in CPN at least 1.8-fold up- or down-regulated in Cnp1 
mutants. Surprisingly, we found only a modest number of differentially 
regulated genes in Plp1 null mutants in CPN over time, as illustrated in Fig. 19 
A (left panel). We detected more down-regulated genes in Cnp null in contrast 
to Plp null samples in neurons, where no trend towards up- or down-regulation 
is obvious. The analysis of WM samples (Fig. 19 A, right panel) revealed 
differential expression of >2000 genes in both mutants during the time course. 
In WM dramatic changes in differential expression can be observed already at 1 
month of age in Cnp1 mutant mice, which even increased at later time points 
and remained constantly high. Similarly as for CPN a strong tendency towards 
gene down-regulation can be observed. In contrast to the Cnp1 mutant 
animals, Plp1 null samples show a different pattern in WM over time. The 
number of affected genes remains rather constant, with a slight peak at the 3 
months time point, and the total number of differentially expressed genes is 
smaller compared to Cnp1 mutant mice (Fig. 19 A, lower right panel). In 
contrast to the analysis of neurons, Plp1 profiles in WM show a slight trend to 
more down-regulated genes.  
In CPN samples of Plp and Cnp mutants 104 and 412 genes were differentially 
expressed, respectively. Of these genes, 40 showed altered gene expression in 
both mutants (Fig. 19 B, upper left panel), covering 40% of deregulated genes 
in Plp1 mutants. In WM samples of Plp1 and Cnp1 deficient mice were 1204 
and 1364 genes significantly deregulated, respectively. 657 genes were 
commonly affected in Plp1 and Cnp1 mutants, representing an proportion of 
~50% of the genes found in both mouse models (Fig. 19 B, upper right panel). 
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Direct comparison of deregulated genes in CPN (598 genes) versus WM (2110 
genes) revealed 180 overlapping genes (Fig. 19 B, lower panel). 
In summary, loss of Cnp1 leads to more dramatic changes in gene expression 
over time compared to the Plp1 mutants. The affected genes are predominantly 
down-regulated in Cnp1 mutant samples, while such tendency is hardly 
detected in the Plp1 mutant mice. However, a significant overlap of 
dysregulated / deregulated genes between Cnp1 and Plp1 knock-out animals 
can be observed, as well as a number of genes deregulated both in neurons 
and WM.  
 
Fig. 19: Distinct gene expression responses in CPN and WM of Cnp1 versus Plp1 
mutants. 
(A) Total numbers of up- and down-regulated genes at each time point are shown; gene 
selection criteria were as follows: adj. p.val < 0.001, fold change (FC) > 1.8. Up-
regulated genes are plotted as red bars and down-regulated genes as blue bars. The 
number of deregulated genes in neurons is substantially higher in the more severely 
affected Cnp1 mutants when compared to Plp1 mutants. The difference in numbers of 
deregulated genes in WM samples are less pronounced between the genotypes.  
(B) Venn diagrams illustrating a high extend of commonly deregulated genes between 
Plp1 and Cnp1 mutant mice in CPN (upper left panel) and WM (upper right panel). 
Comparison of differentially regulated genes in neurons versus WM reveals a large 
overlap (lower panel). 
6.2.7 Gene set enrichment analysis 
To obtain a global view of deregulated genes, that, for example, belong to a 
certain molecular pathway, we employed Gene Set Enrichment Analysis (GSEA) 
to examine changes in a priori defined gene sets. GSEA is a computational 
method that determines whether a defined set of genes shows statistically 
significant, concordant differences between two biological states, e.g. 
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phenotypes (Mootha et al., 2003; Subramanian et al., 2005). GSEA was 
performed with 5214 gene sets obtained from Molecular Signature Database 
(MSigDB) at the Broad Institute (http://www.broadinstitute.org/gsea/). An 
example of a gene set with significantly enriched genes affected by loss of Plp1 
is illustrated in Fig. 20 A and B. It depicts a typical enrichment score curve for 
the gene set "COMPLEMENTKEGG" which is defined by genes involved in the 
classical complement cascade annotated by KEGG (Kanehisa et al., 2008). We 
used "Signal-to-Noise ratio" (SNR) statistics to rank the genes according to their 
correlation with either WT (red) or Plp1-/Y (blue) samples. In Fig. 20 A , the 
graph shows enrichment towards the WT samples, implying that a loss of Plp 
leads to a down-regulation of the complement cascade in CPN at the age of 3 
months. In WM samples (Fig. 20 B), genes involved in the classical complement 
cascade appear unaffected by the loss of Plp1. A summary of selected gene 
sets, which were significantly enriched in Cnp1 and Plp1 mutant mice are 
depicted as a heat map in Fig. 20 C. Similar patterns of gene set shifts were 
observed in both mutants in CPN and WM. The only exception for WM samples 
are genes involved in cholesterol biosynthesis, which exhibit a shift to down-
regulation in Plp1 mutants at all time points examined, whereas Cnp1 mutants 
display slight up-regulation at all time points. 
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Fig. 20: GSEA Enrichment Score curves 
Gene set enrichment analysis (GSEA) was performed with 5214 different gene sets 
obtained from Molecular Signature Database (MSigDB) at the Broad Institute (MIT). 
"Signal-to-Noise ratio" (SNR) statistics were used to rank genes according to their 
correlation with either wild-type samples (red) or Plp -/Y (blue). The graph on the bottom 
of each panel represents the ranked, ordered, non-redundant list of genes. Genes on the 
far left (red) show a higher correlation with wild-type samples, whereas genes on the far 
right (blue) correlated the most with Plp1-/Y samples. On each panel, the vertical black 
lines indicate the position of each of the genes of the studied gene set in the ordered, non-
redundant data set. The green curve corresponds to the ES (enrichment score) curve, 
which is the running sum of the weighted enrichment score obtained from GSEA 
software. (A) shows that genes belonging to the complement gene set (includes 19 genes) 
correlate with three months old WM samples from wild-type (WT) mice and not Plp1-/Y 
mice; the high significance of the enrichment in WT is expressed in the values of ES = 
0,67 and NOM p-val = 0,002. (B) No significant changes in the  enrichment of the 
complement gene set in any of the genotypes at one months time point (ES = -0,34, NOM 
p-val = 0,629). (C) Summary of selected gene sets over all time points in callosal 
projection neurons (CPN) and corpus callosum white matter (WM). Up-regulated gene 
sets and down regulated gene sets with a NOM p-val > 0,05 are indicated in red and 
green, respectively. 
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6.2.8 Differentially expressed genes in CPN can be separated into 
three main groups 
The aim of our study was to elucidate neuronal responses triggered by the loss 
of major myelin proteins. We therefore focused on the CPN dataset and in 
particular on the Cnp1 mutants, because they develop a more severe 
pathology, which is already detectable at 1 month of age. We used a two-way 
ANOVA analysis to identify differentially expressed genes in CPN of Cnp1 and 
Plp1 mutants. For every single probe set, the effects of genotype (WT,  
Cnp1-/- and Plp1-/Y), age (1, 3, 6, and 12 months), and the interaction 
between genotype and age were evaluated. We chose differentially regulated 
genes with a p-value < 0.001 for the interaction and an average expression of 
at least two standard deviations above background for further cluster analysis. 
In Cnp1 mutants, 666 genes fulfilled the criteria, and in Plp1 mutants 161 
genes. Detailed characterization of deregulated genes was done by partitioning 
clustering in order to group genes according their expression profiles over the 
time course of the experiment. To improve partitioning clustering, all 
significantly regulated genes were scaled to mean = 0 and standard deviation = 
1. By transforming the selected genes, the influence of differences in 
expression levels or fold changes were minimized. For unsupervised partitioning 
clustering, the K-means method was employed to group selected genes based 
on their expression profiles into 9 clusters. Repeated clustering resulted in 3 
classes of clusters as depicted in Fig. 21 : 
• Cluster group one includes genes, which are up- or down-regulated in 
mutants at all time points (Fig. 21 A). 
• Cluster group two showed differential expression only at the 3 months 
time point (Fig. 21 B) 
• Cluster group three contains genes, which exhibit expression changes 
starting at the 6 months time point (Fig. 21 C).  
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K-mean clustering was independently performed for genes differentially 
regulated in Cnp1 and Plp1 mutant CPN. Selected members of each cluster are 
listed in Appendix A, Appendix B and Appendix C.  
  
Fig. 21: K-means clustering of affected genes into similar profiles 
K-mean clustering separated 2-way ANOVA significant genes (p val < 0.001, average 
expression > 2 * SD) into 6 clusters. The diagrams of clusters A to C show transformed 
and called expression values (y-axis) obtained by microarray analysis for each time point 
(x-axis). Each group is represented by a prototypical expression profile. For each group 
the corresponding graph is drawn for Plp1-/Y (blue) and Cnp1-/- (red) mutants both for 
up-regulated (A, B, C) and for down-regulated in the knock-outs (A’, B’, C’). Adjacent 
Venn diagrams illustrate overlapping genes in both mutants. (A, A’) Genes that are 
expressed at higher/lower levels in Cnp1 -/- and Plp1 -/Y mutants at all time points; (B, 
B’) genes that exhibit only expression changes at 3 months and (C, C’) at 6 months time 
point. 
 
Following our initial aim to identify differentially regulated genes in CPN in 
myelin mutant mice to uncover neuronal responses to loss of either Plp or Cnp 
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and based on the fact that we identified a rather modest number of 
differentially expressed genes in Plp1 mutants in contrast to Cnp1 mutants, we 
focused our subsequent analysis on samples derived from Cnp1 mutants. 
6.2.9 Gene Ontology annotation of co-clustered genes 
The functional interpretation of microarray datasets still represents a time 
consuming and challenging task. In order to facilitate the annotation of 
microarray data we took advantage of the Gene Ontology (GO) consortium 
(Ashburner et al., 2000). GO provides a structured, controlled vocabulary for 
describing the function of given gene products in an organism. Three separate 
ontologies are provided:  
• Biological process (BP) describes the biological objective to which the 
gene product contributes. 
• Molecular function (MF) describes the biochemical activity of a gene 
product. 
• Cellular component (CC) refers to the place in the cell in which a gene 
product exerts its activity.  
To group the members of all clusters according their functional annotation, we 
extracted gene ontology categories shown for all six clusters employing the ID 
converter from Babelomics suite (Al-Shahrour et al., 2005; Al-Shahrour et al., 
2006). GO terms were further analyzed and grouped according to their 
enrichment in each cluster using the “Blast 2 Go” application (Götz et al., 
2008). A representation of enriched GO categories for each cluster is illustrated 
as pie charts in Appendix D, Appendix E and Appendix F. 
6.2.10 Network integration and visualization 
We used the Gene Ontology (GO) (http://www.geneontology.org/) and Kyoto 
Encyclopedia of Genes and Genomes KEGG (www.genome.jp/kegg.html) 
databases to functionally annotate the gene sets that were obtained by  
K-means clustering. We used the Visual Analysis Tool for Biological Networks 
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and Pathways (VISant, version 3.68) http://visant.bu.edu/) to integrate and 
visualize selected gene set clusters of CPNs from Cnp1 null mice Fig. 21. We 
focussed on two clusters: (1st) those that were up- or downregulated in Cnp1 
null mutant CPNs at all time points which we refer to as the  
Cnp1-/- _CPN_CORE network (CCN) and (2nd) those that deviated at 3 months 
(referred to as the C3N) . We first uploaded the CORE probesets into VISant 
and visualized up- and downregulated gene products as red and blue circles 
(referred to as ‘nodes’), respectively (Fig. 22). Next we used the VISant-
database predictome of protein linked interactions to connect nodes based on 
published interactions (referred to as ‘edges’ and drawn as straight and 
undirected lines between respective nodes). We used the information available 
for the human protein collection (containing > 90.000 entries compared to the 
mouse collection with only roughly 6,000 entries) that has been extracted from 
several large-scale experimental and literature extracted databases (see 
http://visant.bu.edu/ for interaction statistics and methods selected). The 
inferred CORE network was arranged using the ‘elegant relaxation’ mode and 
subsequently re-arranged manually and extended using literature searches 
using iHOP (http://www.ihop-net.org/UniPub/iHOP/) and is depicted in Fig. 22. 
The CCN comprises 62 query (27 are upregulated and 26 downregulated genes) 
and 370 inferred nodes (in total 432). The number of edges is 424. The 
interaction network can be described as scale-free by an asymptotic function 
with Y = 65,47 * X1,36 where Y is the number of nodes and X the number of 
edges. 
We subgrouped nodes in so-called ‘metanodes’ both based on internal 
connectivity’s and knowledge-driven with respect to putative entities relevant 
for axonal biology. The following metanodes of the CORE network were defined 
(see Table 5 for annotations):  
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Table 5: Metanode annotation 
‘Filaments’   structural proteins likely to be relevant for axonal stability 
‘Motors’   motor proteins involved in anterograde and retrograde  
   axonal transport 
‘Ribosome’   ribsosomal or ribosome-associated proteins involved in  
   translation 
‘Signaling’   proteins with a presumptive function in cellular signalling  
   processes 
‘Lipds’   enzymes and proteins involved in lipid synthesis and  
   homeostasis 
‘Apoptosis’   proteins related to cell death control 
‘Ubiquitin’  proteins involved in controlled protein degradation/stability 
‘Metabolism’  enzymes involved in metabolic processes 
Two transcription-related metanodes were subgroup based on internal 
connectivities and named by the corresponding ‘hub’ protein showing the 
highest connectivity: 
‘ID2’   including the HLH factor ID2 and the MADS box protein  
   MEF2C 
‘MED1’  factors interconnected by TP53 
A third transcription-related metanode was arbitrarily grouped: 
‘HBP1’ proteins surrounding the HMG-Box factor HBP1 
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Fig. 22: Integrated ‘core’ network of genes regulated at all timepoints in CPNs of 
Cnp1 null mutant mice (CCN). 
(A) Gene-cluster that were either up- (left) or downregulated (right) in Cnp1 null mutant 
CPNs were selected for network expansion and visualization. From 72/36 probe sets, 
28/31 were annotated either with a GO or KEGG annotation and uploaded into VISant. 
27/26 genes were subsequently subgrouped in functionally related subclusters. (B) 
Visualization of the CCN network comprised of up- and downregulated genes (nodes) 
depicted as blue and red circles, respectively. First level interactors are depicted as 
smaller circles in grey. Connections (edges) between nodes represent interactions either 
downloaded from the predictome database integrated in the VISant tool or from literature 
scans with iHOP or PubMed. 
The CORE network was expanded with the GO/KEGG annotated gene symbols 
corresponding to the ‘3M cluster’. These additional nodes were not further 
extended by the predictome database to keep the core network dense. The 
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resulting combined network of genes regulated at 3 months was termed Cnp1-
/-_CPN_3M Network (C3N). Nearly half of the genes additionally regulated at 
3M could be grouped to the already existing metanodes defined for the CORE 
network (Fig. 23). The C3N comprises 101 query (75 are upregulated and 27 
downregulated genes) and 360 inferred nodes (461 in total). The number of 
edges is 577. The interaction network can be described as scale-free by an 
asymptotic function with Y = 160,7 * X1,57 where Y is the number of nodes and 
X the number of edges. 
We observed that the complexity and internal connectivity of the C3N was 
higher as compared to the CCN. This was mainly due to a large increase in 
nodes and edges in the Signaling and Ubiquitine clusters, arguing for an 
enhanced demand of regulatory functions at 3 months in CPNs of Cnp1 null 
mutant mice (Fig. 24). 
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Fig. 23 Integrated ‘core’ network of genes regulated at all timepoints and at 3 
months in CPNs of Cnp1 null mutant mice (C3N). 
(A) Gene-cluster that were either up- (left) or downregulated (right) in Cnp1 null mutant 
CPNs at all timepoints and at 3 months were selected for network expansion and 
visualization. From 403/75 probe sets, 162/48 were annotated either with a GO or KEGG 
annotation and uploaded into VISant. 75/26 genes were subsequently subgrouped in 
functionally related subclusters. (B) Visualization of the C3N network comprised of up- 
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and downregulated genes (nodes) depicted as blue and red circles, respectively. Large 
circles correspond to genes regulated at all time points, whereas smaller circles depict 
genes found to be regulated at 3 months. First level interactors are depicted as smaller 
circles in grey. Connections (edges) between nodes represent interactions either 
downloaded from the predictome database integrated in the VISant tool or from literature 
scans with iHOP or PubMed. 
 
Fig. 24: CCN and C3N network properties. 
(A) CCN and (B) C3N network visualization with all functional grouped nodes depicted 
as collapsed metanodes. Edges were weighted based on shared components, different 
colours represent different methods that identified interactions. Red metanodes represent 
grouped genes that are in average upregulated, blue downregulated and grey unregulated. 
Yellow metanodes refer to transcription related gene sets. (C) Signaling related metanode 
of the CPN and (D) C3N network. Note the change of query and level 1 interactors and 
the enormous increase in connectivity. (E) Number of CPN (blue) and C3N (red) nodes 
plotted as a function of connected edges. Depicted in black is part of a reference protein 
interaction network downloaded from VISant. Note. That both CPN and C3N curves are 
more steep indicating a high number of hubs (that I shighly connected nodes) within the 
respective networks. 
In summary, the network level analysis revealed core sets of functionally 
grouped genes that are most likely relevant for the adaptation to the axonal 
stress caused by the lack of the CNP1 in oligodendrocytes. Among the most 
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interesting findings is the tight coupling of phosphor-signaling and structural 
components as well as the unexpected link towards an altered lipid 
homeostasis. Equally important with respect to current hypotheses regarding an 
trophic and/or metabolic support of axons by oligodendroglial cells are our 
findings of the coordinated downregulation of the pyruvate dehydrogenase 
kinase 1 (Pdk1) and up-regulation of key metabolic enzymes involved in the 
mitochondrial NADH shuttle, which seems to be required when lactate rather 
than glucose might be available as energy source. 
6.2.11 Loss of Cnp1 mediates transcriptional changes in CPN for 
genes involved in TP53 relevant pathways  
Another focus of this study was to identify differentially expressed genes, which 
respond already at the 1 month time point to loss of major myelin proteins. 
These genes may reflect an early compensatory response of neurons to loss of 
glial support. We thus examined the CCN group (Fig. 21 A, A’) to identify 
potentially promising candidate genes. Candidate genes were validated using 
QRT-PCR. One of the most interesting genes, which exhibited a highly 
significant constitutive up-regulation exclusively in Cnp1 null mutants, is the 
mediator complex subunit 1 (Med1, p-value < 0,0001). The MED1 protein, 
interacts with nuclear receptors and transcription factors to form the mediator 
coactivator complex, which facilitates promoter recruitment and function of RNA 
polymerase II and associated general transcription factors. First identified as a 
part of a defined complex in yeast, Med1 is evolutionarily conserved and 
belongs to a multi-protein complex that contains approximately 30 subunits. It 
is believed to connect transcriptional activators with the RNA polymerase II 
transcription machinery and appears to be essential for most, but not 
necessarily all, RNA polymerase II-mediated transcription. There are four 
different splice variants annotated for Med1 in ENSEMBL. Variant 1, 3, and 4 
code for transcripts ranging from 4900 bp to 5500 bp, whereas variant 2 is a 
shorter isoform lacking the 3’-end (2100 bp) shown in Fig. 25 A. The 
MOUSE430 A 2.0 microarray (Affymetrix) allows to distinguish between variant 
2 and the longer variants 1, 3, and 4. In contrast to probesets coding for 
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variant 2 displaying no differential expression, probe sets for the variants 1, 3, 
and 4 revealed a strong up-regulation in Cnp1 null mutants. Microarray 
expression profiles of Med1 are shown in Fig. 25 B. 
 
Fig. 25: Med1 mRNA expression is up-regulated in Cnp1 null mutants. 
(A) Four splice variants are annotated in Ensembl for Med1. (B) Time course expression 
profile of variant one and three shows constitutive higher expression in Cnp1 mutant 
CPN compared to WT and Plp1 mutant mice. Short variant 2 shows a similar expression 
profile for all groups over time. Plotted are normalized intensities; triangles represent 
mean values of three biological replicates; circles represent expression values for each 
biological replicate separately. (C) QRT-PCR results of whole cortex samples obtained 
from the same biological replicates used for microarrays (n=3). Significant up-regulation 
of Med1 at 12 months of age can be observed, changes at the 3 months time point were 
not significant. Error bars indicate standard error of the mean.  
Using appropriately-sized spates we isolated total RNA from whole Cx at 3 and 
12 months time points from the same brain samples, which were profiled by 
microarray analysis. Reverse transcribed cDNA was used for QRT-PCR. Relative 
quantification (ddCt-method) of Med1 using specific hydrolysis probes revealed 
no difference at 3 months between WT, Cnp1 and Plp1 mutant samples, in 
contrast to the 12 months time point where we could observe a significant 
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higher expression in Cnp1 mutants (Fig. 25 C). Med1 in general was 
characterized by very low expression levels close to the detection limit (average 
Ct-values = 37, Beta actin (Actb) Ct = 23). 
Genes, which were significantly down-regulated over all examined time points 
included cytokeratin 12 (Krt12) and human pituitary tumor transforming gene 
(Pttg1). Krt12 showed a complete loss of transcripts in CPN of Cnp1 mutants, 
shown in Fig. 26 A, which could be validated with QRT-PCR illustrated in Fig. 26 
A''. On microarrays, no expression for both genes in WM samples was detected 
(Fig. 26 A'). The mRNA expression profiles obtained by microarrays of Pttg1 
revealed a down-regulation in CPN and WM of Cnp1 mutants in all time points, 
depicted in Fig. 26 B, B'. Down-regulation of Pttg1 could be validated by QRT-
PCR in Cx samples for 12 months, but not for 3 months, where QRT-PCR 
indicated no significant difference in relative mRNA expression levels of Pttg1, 
as shown in Fig. 26 B''. 
 
Fig. 26: mRNA expression profiles of Krt12 and Pttg1 
(A) Microarray profiles of Krt12 mRNA showed complete loss of transcripts in Cnp1 
mutants at all time points. (A') Krt12 could not be detected at the level of transcription in 
WM samples. Plotted are normalized intensities; triangles represent mean values of three 
biological replicates; circles represent expression values for each biological replicate (n = 
3). (A'') QRT-PCR of three independent animals per genotype (n = 3) using cDNA 
derived from whole Cx validate findings from microarray data for Krt12 (hydrolysis 
probe assay). Plotted are relative expression levels normalized to Actb. Error bars 
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represent SD. (B) Gene expression profiles of Pttg1 showed decreased levels of 
transcription in Cnp1 mutants over all time points. (B') Corresponding microarray 
profiles of WM samples showed the same tendency as in CPN. Plotted are normalized 
intensities; triangles represent mean values of three biological replicates; circles represent 
expression values for each biological replicate (n = 3). (B'') QRT-PCR of three 
independent animals per genotype (n = 3) using cDNA derived from whole Cx validate 
findings from microarray data for Pttg1 (hydrolysis probe assay) for the 12 month time 
point. Results for the three months time point exhibit a tendency towards down-
regulation, but the differences are not significant. Plotted are relative expression levels 
normalized to Actb. Error bars represent SD. 
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7 Discussion 
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7.1 Cell purification techniques in the CNS 
The cellular complexity in the CNS of mammals is enormous. The number of 
distinct neuronal cell types in the mammalian 'neurome' (103-104) is likely to be 
within an order of magnitude of the genes in the mammalian genome (2-3x 
104). It seems very unlikely that single genes specify or can serve as markers 
for single cell types making the identification of distinct cell types extremely 
challenging. Most applications are limited by the lack of identifying single cell 
populations.  
7.1.1 Identification methods 
There are several approaches available to identify specific cell types. All of them 
have their benefits and limitations, which are briefly discussed here. The 
simplest method does not inlcude no labelling at all; cells are chosen randomly 
or based on position, morphology or electrophysiology. However, identification 
of cell types is post-hoc, so rare types can be missed and also the 
reproducibility is very difficult to assess. A similar approach involves unspecific 
cell labelling such as Nissl staining. An example is the dye thionin that 
intercalates in (predominantly ribosomal) nucleic acids, and labels therefore any 
cell on the slide. Nissl staining methods allow identification of cell types upon 
morphology (size, arborization), and position and, most importantly for our 
approach, are LCM compatible (Xinyu Zhao et al., 2001b; Hinkle et al., 2004a). 
Nissl staining becomes especially interesting for tissues where alternative 
methods are limited, as is the case for human brain samples.  
Immunocytochemical labelling of cells with antibodies against known markers 
serves to distinguish between specific cell types. This approach allows the 
integration of several markers at the same time, which enables more precise 
selection of target cells due to several possible combinations. Antibody labelling 
can be performed on living cells for instance in combination with FACS or 
manual sorting. A limitation is the constriction to extracellular epitopes and the 
fact that samples are processed for several hours outside of their physiological 
environment, potentially mediating transcriptional changes in manipulated cells. 
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Antibody labelling can be also employed for LCM on unfixed cryosections 
requiring incubation in aqueous condition, which can compromise RNA integrity. 
However, Greene and colleagues used successfully an antibody against 
Tyrosine hydroxylase on cryosections to identify midbrain dopamine neurons for 
LCM (Greene et al., 2005).  
Identifying cells with a tracer dye is another possibility to label specific types of 
neural cells. Hereby, cells are labelled by stereotaxic injection of fluorescent 
tracers into projection targets. Tracer dyes are absorbed by axons and are then 
retrogradely transported into the cell body. The internal restriction to this 
method is that only projection neurons are targeted, whereas multiple cell types 
can share projection targets. Transgenical labelling is one of the most 
consistent cell type identification approaches. During the last decade, hundreds 
of transgenic mice were generated, which express fluorescent proteins driven 
by cell type-specific promoters or enhancers to label for instance different 
neural cell populations. These mouse lines are compatible with FACS or manual 
sorting to isolate pure cell populations. A major drawback of these mice is its 
incompatibility with LCM. The fluorescent signal gets rapidly lost during section 
preparation. Therefore, we used a mouse line, which expressed a nuclear 
variant of EYFP under the control of the Thy-1 promoter (Rossner et al., 2006). 
Nuclear localization of EYFP leads to cellular signal enhancement and is 
compatible with LCM.  But generation of reliable reporter mice is laborious and 
cost-intensive, and limited availability of cell-type specific promoters further 
hampers the generation of these useful tools. In short, the choice of the 
appropriate labelling method depends strongly on the downstream analysis and 
funds. 
As for labelling methods, many different approaches have emerged to isolate 
specific cell populations from brain. We discuss here briefly the most commonly 
applied methods in neuroscience. 
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7.1.2 Cell Isolation techniques in CNS 
7.1.2.1 RNA-tagging  
RNA tagging provides a way to purify mRNA from a genetically labeled cell 
population without the need to identify and isolate cells. A FLAG-tagged 
poly(A)-binding protein (PABP) is expressed in the population of interest, where 
it binds to polyadenylated mRNA. The tissue is fixed, to cross-link the PABP 
covalently to the mRNA, and then homogenized. mRNA from the cell population 
of interest is affinity-purified by anti-FLAG antibodies. The gene expression of 
ciliated sensory neurons in C. elegans was transcriptionally profiled used mRNA 
tagging (Kunitomo et al., 2005). In a different study polyadenylated RNAs from 
photoreceptors in D. melanogaster were enriched using this method (Z. Yang et 
al., 2005). Expression of known cell type markers validated in both cases 
reliability of this technical approach.  
7.1.2.2 Single-cell aspiration  
Following patch clamp recording, cytoplasmic contents can be aspirated. This 
approach enables the combination of electrophysiology and anatomy of 
transcriptomic or proteomic techniques in the same cell. Due to the tiny sample 
amounts obtained from single cells, which represent only a fraction of the 
corresponding population, high measurement noise and frequent false-negative 
results are a major drawback of this approach. These techniques were 
successfully employed by (J Eberwine et al., 1992), (Hinkle et al., 2004b), 
(Cauli et al., 2000) and (Toledo-Rodriguez et al., 2004).  
7.1.2.3 Manual sorting 
Manual sorting is the isolation of dissociated cells expressing a specific marker 
under a fluorescence microscope, using for instance a glass pipette for 
collection. This approach yields usually high purity of collected samples and it is 
applicable to isolate adult cells as well as dimly labeled cells. One of the pitfalls 
is the low RNA yield, which further requires RNA amplification for microarray 
analysis. A second drawback is the time-consuming procedure which may have 
an impact on transcriptional changes. However, transcriptome profiling of 
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twelve neuronal subpopulations could be performed employing manual sorting, 
where neurons of the forebrain were distinguished based on specific expression 
of fluorescent proteins (Sugino et al., 2006). RNA was successfully amplified 
and hybridized to microarrays. The authors could identify several novel cell type 
specific marker genes using this approach.  
7.1.2.4 Fluorescence activated cell sorting 
High purity of neuronal populations can be achieved using live-cell sorting 
because dissociated cells can be stripped completely bare of contaminating 
factors such as neuronal fibers, extracellular matrix and monocytes. In addition, 
such samples provide RNA in a pristine form because they are not subjected to 
freezing or fixation. Moreover, FACS can sort up to millions of cells depending 
on the source and can therefore be used for microarrays without additional 
amplification of RNA. On the other hand, there are also limitations inherited in 
this approach. Samples have to be handled for several hours to prepare them 
for FACS sorting, during which changes in gene expression can occur. In 
addition, cells have to be treated with proteases and are therefore removed 
from their cellular context, which represents a huge impact. Thus, during 
preparation, cells are exposed to enormous stress and it is likely that they react 
also on the level of transcription. Interpretation of microarray data obtained by 
this approach is therefore complicated because stress responses of isolated 
cells could mask relevant changes in gene expression. Neural cells, being in 
general highly fragile, can be FACS-sorted until P25 - P35, depending on the 
cell type of interest, restricting this technique to the analysis of embryonic and 
early postnatal stages. However, developmental questions such as cell type 
differentiation can be addressed using this technique in combination with 
numerous available reporter mice.  
One of the first successful applications of FACS on neural samples provided 
insight into the transcriptome of touch receptors of C. elegans, which were 
labelled by GFP (Y. Zhang et al., 2002). Similar progress has been made in cell-
type-specific expression profiling in the mammalian nervous system. GFP-
expressing neural crest stem cells were FACS-sorted and profiled at several 
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developmental stages as they differentiate into Schwann cells, revealing 
hundreds of genes likely to be involved in this process (Buchstaller et al., 
2004). Transcription profiles derived from specific neuronal subpopulations in 
the mammalian CNS were generated using live-cell sorting (Arlotta et al., 
2005). In this study, the authors could detect several genes, which were only 
expressed by specific neuronal subpopulations, and therefore discovered new 
subpopulation specific markers, which could be further validated by 
immunohistochemstry (IHC) and in-situ hybridization (ISH). 
In the present study, we applied FACS for highly purifying acutely-isolated 
specific glial cell types from developing mouse forebrain. We took advantage of 
three different mouse lines, which express fluorescent proteins driven by cell 
type-specific promoters to identify GPCs (hGFAP-EGFP), MG (Cx3cr1-EGFP), and 
OLs (Plp1-DsRed) (Fig. 5). We dissociated brains of these mice with papain, 
purified fluorescent cells on an automated FACS, and finally extracted mRNA for 
whole transcriptome microarray analysis.  
The applied quality controls demonstrated high microarray performance and 
absence of major batch effects (Fig. 6). Global mRNA expression patterns of 
different glial cell types reflected nicely their affiliation to each other and further 
supported the reliability of the dataset. Expression profiles of several known 
marker genes validated the purity and identity of the isolated cell types (Fig. 7). 
We could detect a significant set of specifically expressed genes for every cell 
type under investigation (Fig. 7). Those genes represent potential new cell 
type-specific markers but need to be further validated with IHC or ISH.   
The use of DNA microarray technology is very attractive for large-scale studies 
of alternative splicing. By measuring the relative amounts of distinct splice 
forms in a variety of tissues, microarrays could both test whether a novel splice 
form really constitutes an important fraction of the gene's transcripts in at least 
some cell types, and reveal its patterns of regulation across a large number of 
different tissues.  
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Taking full advantage of microarray technology to analyze alternative splicing 
poses many challenges for current methodologies. Traditional microarrays are 
designed to measure the total level of expression of a gene, without attempting 
to distinguish between different splice forms (for a review see (Butte, 2002)). 
For example, probe designs and labeling protocols used for microarray 
experiments tend to be biased towards the 3' end of the gene (G.K. Hu et al., 
2001). As each gene is assumed to be expressed as a unit, this is not 
considered to be a problem. By contrast, for alternative splicing it is important 
to have probes throughout all regions of the gene - ideally covering all exons as 
well as splice junctions. 
Alternative splicing also poses new challenges for microarray data analysis. The 
overall expression level of a gene can be represented by a single number and 
can be measured with reasonable accuracy by averaging the signals of many 
probes for the gene (Lipshutz et al., 1999). Individual probes that diverge 
significantly from the average profile are generally considered to be outliers and 
are excluded from the analysis (Li and Wong, 2001). But such 'inconsistent' 
results (in which a subset of probes show a large change in signal that is not 
seen in other probes for the gene) are exactly what alternative splicing will 
cause. Thus demonstrating that the probes considered by standard expression-
data analysis to be 'noise' are actually reproducible signals, indicative of 
different patterns of regulation of multiple splice forms is highly challenging. 
Despite these challenges, there is now broadly reproducible evidence that 
alternative splicing can be detected using microarrays. For example, (G.K. Hu et 
al., 2001) used standard Affymetrix array designs to search for evidence of 
alternative splicing in 1,600 rat genes, performing hybridizations with 10 normal 
tissue samples. They found that 268 genes (17%) showed signs of alternative 
splicing, and validation by QRT-PCR indicated that about half of these 
represented genuine alternative-splicing events. This work clearly demonstrates 
that microarrays can detect alternative splicing, but many types of alternative 
splicing have probably been missed in this study because of technical limitations 
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such as 3' labeling bias and the absence of probes designed to detect splice 
junctions.  
Exon level analysis on our dataset revealed a large number of potential 
alternative splicing events between different cell types, which have to be 
further validated using QRT-PCR. The MOUSE Exon 1.0ST array used in this 
study provides expression levels for single exons but not for exon-exon 
junctions rendering transcript variant prediction difficult. 
Our generated datasets may serve as a seed towards a transcriptome database 
housing genome-wide gene expression values for main glial cell types in the 
CNS. Our experimental approach can also be applied to study transcriptional 
changes occurring in specific cell types in pathological conditions such as 
neurodegeneration. The technique-inherited limitation to early postnatal stages 
does not allow analysis of more disease-relevant changes in the adult CNS. The 
generation of such datasets could offer resources to the neuroscience 
community to better understand functions of neural cell types in their 
physiological context. Databases of cell type-specific transcriptome data 
complement existing online available resources, which contain regional gene 
expression patterns like the Allen brain atlas (www.brain-map.org) and GENSAT 
(www.gensat.org). These in situ tools correlated to a high degree with our 
expression data (data not shown) and therefore served as an invaluable 
resource for cross-validation. The genome-wide coverage of microarrays 
enables us to quantitatively detect much more cell type specific differential 
expressed genes. In particular the usage of whole transcriptome microarrays, 
designed for analysis of alternative spicing events, provides powerful tools to 
look into cell type-specific changes which can hardly be detected using standard 
techniques like IHC or ISH. 
7.1.3 Laser capture microdissection  
Laser-capture microdissection (LCM) is a method to procure subpopulations of 
tissue cells under direct microscopic visualization. LCM technology can harvest 
the cells of interest directly or can isolate specific cells by cutting away 
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unwanted cells to give histologically pure enriched cell populations. LCM is most 
commonly performed on cryo sections, which are subsequently dehydrated to 
prevent RNA degradation. Cryo section can also be subjected to several staining 
protocols (see section 7.1.1). To obtain CNS tissue, brains are removed from 
the skull and directly frozen on dry ice; therefore cell status is captured 
immediately after death. To perform FACS, manual sorting or single cell 
aspiration the cells are exposed to enormous stress for up to several hours after 
displacement from their physiological environment. Expression of immediate 
early genes for instance is induced after 10 min in a stress paradigm 
(Honkaniemi et al., 1994; Burmeister et al., 2008), demonstrating that cells 
change rapidly their pattern of transcription to adapt to new stress situations. 
Physiological relevant differences in vivo could be masked by stress-induced 
changes in gene transcription ex vivo. LCM method provides a snap shot of the 
transcriptome taken at the time when animal was sacrificed.   
LCM was successfully applied in several studies to purify specific cell types fom 
the CNS. Midbrain dopaminergic neurons have been a favored target for such 
investigations, both because of their clinical importance in neurodegenerative 
disorders such as Parkinson’s disease and because they are readily labeled by 
antibodies to tyrosine hydroxylase (TH), the enzyme responsible for the 
production of dopamine. Two groups (Chung et al., 2005), (Greene et al., 
2005) compared dopaminergic neurons from neighboring midbrain regions, the 
ventral tegmental area (VTA) and the substantia nigra, to identify genes that 
might contribute to the higher susceptibility of the latter population to 
neurodegeneration in Parkinson’s disease. Both studies identified numerous 
genes that had statistically significant differential expression. (Yao et al., 2005) 
compared VTA dopaminergic neurons with corticostriatal pyramidal cells 
retrogradely labeled by striatal injection of fluorogold. Several dozen genes 
were identified as differentially expressed using very rigid criteria. Several 
genes enriched in corticostriatal neurons match those found in this cell type by 
other investigators using cell-type-specific expression analysis (Arlotta et al., 
2005; Sugino et al., 2006). Altogether, these studies demonstrate that LCM 
achieves sufficient purity and RNA integrity, and thus serve as a useful 
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complement to the cell-sorting approaches outlined in the previous section, 
especially because it can be more readily applied to the study of human tissue. 
We could in a different study successfully capture transcription profiles of 
human hippocampal CA4 neurons of schizophrenic patients and healthy controls 
(Wichert et al. manuscript in preparation).  
7.2 Gene expression changes in CNS cell subpopulations 
in Cnp1 and Plp1 deficient mice over time  
The central aim of the presented thesis was to determine gene expression 
profiles (i) of white matter and (ii) of cortical projection neurons in wild-type 
and two genetically modified mouse lines that lack functional Plp1 and Cnp1 
genes, respectively. The corresponding proteins, PLP and CNP, are major 
constituents of CNS myelin sheaths, which engulf axons to enable rapid 
saltatory signal propagation. Somewhat surprisingly, however, Cnp1 and Plp1 
null mice display first signs of axonal damage at around 3 months of age before 
structural myelin alterations, signs of demyelination or behavioral phenotypes 
become apparent (Klugmann et al., 1997; Lappe-Siefke et al., 2003). This 
observation led to the hypothesis that a still unknown glial support mechanism 
(or mechanisms) may be missing in the respective mutant mice causing local 
axonal stress and damage (Klugmann et al., 1997; Lappe-Siefke et al., 2003). 
Axonal loss is a central but still underappreciated mechanism that is part of the 
phenotypes observed most likely in all neurodegenerative diseases. The 
processes that underlie axonal degeneration and eventually secondary neuronal 
loss are not very well understood. The causes of human neurodegenerative 
diseases are often genetically highly complex and display many individual and 
local differences. The investigation of the mechanisms leading (or protecting 
from) axonal damage in patients suffering from Multiple Sclerosis (MS) and in 
corresponding mouse models is further complicated by inflammatory processes 
that likely contribute to the disease severity (De Vos, 2000; Stagi et al., 2005; 
Stagi et al., 2006). Axonal damage can be observed upon acute ischemic 
lesions, however, corresponding animal models display a high experimentally 
variability rendering precise molecular investigations difficult. For several 
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reasons, the genetic mouse models and experimental strategy we employed to 
study axonal degeneration offered several advantages and opportunities:  
(i) By introducing a transgenic and microdissection-compatible label (a 
nuclear expressed GFP variant), we were able to isolate cell bodies 
and the corresponding RNAs of cortical projection neurons at high 
purity whose axons were most likely evenly affected by the glial 
defect.  
(ii) Axonal damage occurs physiologically in a progressive manner, 
ranging from ‘normal’ to pathological conditions that is characterized 
by enhanced debris clearance by activated microglia and is 
accompanied by a ‘stress-response’ of astroglial cells particularly in 
white matter tracts. Both our time-course, as well as the investigated 
cell types, take this into account 
(iii) Age-, sex-matched and cell-type-enriched analyses reduced the 
experimental variability and -most likely- improved the specificity of 
the results. 
(iv) We hypothesize that the corresponding neuronal gene expression 
profiles reflect direct markers of the disease mechanisms eventually 
detectable before histological or behavioral phenotypes. 
7.2.1 QC controls see  
Expression profiling from LCM derived samples inherits several challenges 
including limited RNA amount/quality and purity of sample isolation 
(contamination). We isolated RNA from 700 - 800 CPN yielding in minute 
amounts of total RNA (<1 ng), therefore RNA quality as well as quantity could 
not be evaluated. Isolated RNA was subjected to 2-round T7-RNA polymerase-
mediated linear amplification, yielding in up to 10µg amplified RNA. From 
previous observations, we know that RNA integrity is compromised during cryo-
section preparation, dehydration-, and LCM-procedure (data not shown) but is 
still suitable for reliable microarray analysis. In order to draw valid conclusions 
from microarray data, analysis quality control (QC) parameters have to be 
evaluated critically. Standard QC parameters showed typical values. RNA quality 
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was comparable in all samples under investigation supported by homogeneous 
RNA degradation slopes between the samples, which is a crucial feature. 
Reliability of the dataset was further supported by high correlation of biological 
replicates. Our microarray data met stringent QC criteria and indicate therefore 
high microarray performances. Moreover, results for the cell type specific 
marker gene expression showed high purity of the LCM procedure. 
7.2.2 Correlation of histological parameters with marker gene 
expression 
Although the activation of astrocytes and microglia has been reported in 
previous studies in Cnp1 and Plp1 null mutant mice (Klugmann et al., 1997; 
Lappe-Siefke et al., 2003; Edgar et al., 2009), we performed quantitative 
analyses of immunohistochemical stainings to allow a precise kinetic 
comparison of marker gene expression and protein detection for all time points 
investigated. However, only selected time points were analyzed. 
Oligodendrocytes were stained for nuclear APC (using the CC1 antibody) and 
revealed neither dramatic changes between genotypes nor at different time 
points in the CC. A slight increase in the number of CC1 positive cells was 
observed from 1 month to 12 months old animals. This finding may indicate a 
slightly increased number in oligodendrocytes or could reflect an improved 
detection/higher expression level of APC with the CC1 antibody. Since probably 
not all oligodendrocytes in white matter tracts stain positive for CC1 (M. 
Rossner, unpublished observation), the latter scenario appears to be more 
likely. This finding is, however, in agreement with previous findings (Klugmann 
et al., 1997; Lappe-Siefke et al., 2003) and (Burzyńska, 2007) showing 
normally sized white matter structures in and Plp1 null mice. In the cortex, the 
number of CC1+ cells likely reflecting oligodendrocytes remained also constant 
from 1-6 months. At 12 months, the antibody detected not only small nuclei but 
also large cell bodies of -most likely- pyramidal neurons rendering an 
unambiguous interpretation difficult. That the number of oligodendrocytes most 
probably did not change over time in the CC was corroborated by the 
expression of oligodendrocyte specific genes. Although Plp1 mRNA was reduced 
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to app. 50% of the expression level seen at 1 month, Cnp1 expression (as well 
as other myelin markers such as Mobp or Mbp, data not shown) remained 
constant. The Plp1 and Cnp1 messages were not detected in the corresponding 
null mutants. The gradual down regulation of the Plp1 mRNA with age 
represents itself a novel finding and appears to be a marker for aged white 
matter/oligodendrocytes that has not been appreciated before.  
We also employed histological staining and transgenic labeling to assess the 
number of all cortical neurons, of cortical projection neurons and Purkinje cell in 
WT, Cnp1 and Plp1 mutant mice. In accordance with published data (Klugmann 
et al., 1997; Lappe-Siefke et al., 2003) and (Burzyńska, 2007) we could not 
detect substantially altered numbers of neuronal cells in the cortex as assessed 
by the pan-neuronal nuclear marker NeuN. Likewise, the analysis of the 
transgenically introduced in vivo label of cortical projection neurons did not 
reveal altered cell numbers. In contrast, the numbers of cerebellar purkinje cells 
(PCs) were highly reduced in Cnp1 null mutants at one year of age likely 
explaining the severe motor phenotype at this age. This cell-type specific 
susceptibility is a typical phenomenon of several neurodegenerative diseases 
including Parkinsons disease (Chung et al., 2005; Greene et al., 2005), 
Niemann Pick Type C disease, a neurodegenerative lysosomal storage disorder 
(Ko et al., 2005), Alzheimer (Capetillo-Zarate et al., 2006), and myelinopathies 
such as Pelizaeus-Märzbacher.  We particularly focused in this study on the cell 
death ‘resistant’ CPNs since corresponding gene expression profiles of PCs 
would have been strongly biased by cell death effects rather than serving as 
indicators of axonal stress. 
Immunhistochemical identification of astrocytes was performed with staining 
directed against GFAP, which serves as a reliable marker for a subpopulation of 
activated astroglial cells (Ghandour et al., 1983). Quantitative analyses of 
stained sections revealed an elevated level of GFAP in CC of Cnp1 null mutants 
and a time dependent increase in Plp1 null mutants. At the level of gene 
expression, Gfap mRNA remained constant in WT CC over time but was 
substantially elevated both in Plp1 and Cnp1 mutants with age. Gene 
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expression of another astrocytic marker, S100b, was similarly increasing with 
age in all genotypes. These findings indicate that astrocytes are molecularly 
activated in both myelin mutants but the cell number may remain constant 
(assuming that S100b expression represents a reliable indicator of astrocyte cell 
numbers). The discrepancy of immunohistochemical detection and gene 
expression of Gfap may be explained by different half-lives of protein versus 
mRNA in CC astrocytes. In the Cx, we observed a several fold increase in Gfap 
positive cells in Cnp1 mutants with age peaking at 6 months. Interestingly, this 
peak of astrocyte activation coincides with the peak of axonal swellings and 
collagen deposition in the CC (Burzyńska, 2007), see below. The expression of 
the ‘astroglial’ marker S100b in CPNs was corroborated by inspection of the 
Allen brain atlas (www.brain-map.org), Gfap was not detected in the CPN 
samples. 
Microglia activation was assessed with immunostainings directed against MAC-2 
and IBA1, showing an age dependent increase in Plp1 and Cnp1 mutants. The 
corresponding gene expression profiles depicted the gradual increase of 
microglia markers in CC in a more sensitive and reliable fashion. Particularly, 
Mac-2 expression was robustly detected in both mutant CC samples already at 
3 months further increasing in the 6 and 12 months time points. The Mac-2 and 
Iba1 mRNA profiles correlate well with observations made independently at the 
level of immunostainings (Burzyńska, 2007). 
In summary, marker gene expression profiles very well reflected observations 
made with immunohistochemical analyses such as genotype- and time-
dependent astroglial and microglial activation with constant numbers of 
oligodendrocyte markers in cortical white matter. In general, marker gene 
expression profiles were more sensitive in reflecting the increased disease 
severity seen in Cnp1 mutants compared to Plp1 null mice, further supported by 
total number of deregulated genes at each time point Fig. 19. In CPN the 
pattern of total deregulated gene numbers showed high correlation with 
disease time course suggesting that our expression profiles reflect neuronal 
adaptations to oligodendrocyte dysfunction. In contrast reflect the observed 
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massive transcriptional changes in WM samples more likely the activation of 
astroglia and microglia in cortical white matte tracts than changes occurring in 
deficient oligodendrocytes, rendering the dissection of disease relevant gene 
expression changes rather difficult.  
Therefore we addressed our analysis more to the question how neurons react 
upon loss off glial support on the level of transcription. Due to the fact that we 
detected a broader response in CPN of Cnp1 mutants we focused further 
analysis on this particular mutant. K-mean clustering served as a method to 
build subgroups of genes, which exhibit similar time course profiles. We were 
mainly interested in genes, which respond already at the early time points (1 
and 3 month) when primary changes in transcription are not masked by 
secondary effects. Investigation of genes, which showed up/down regulation at 
all time points, revealed core sets of functionally grouped genes that are most 
likely relevant for the adaptation to the axonal stress caused by the lack of CNP 
in oligodendrocytes. Among the most interesting findings is the tight coupling of 
phospho-signaling and structural components as well as the unexpected link 
towards an altered lipid homeostasis. That changes in lipid regulation cause 
mitochondrial dysfunction were previously shown in several studies (Y Huang et 
al., 2001; F.M. Harris et al., 2003; Chang, 2005; T. Nakamura et al., 2009). 
Contribution of lipid deregulation to development of neurodegenerative 
diseases has been proven by several mouse models reviewed by (Adibhatla and 
Hatcher, 2008). Equally important with respect to current hypotheses regarding 
an trophic and/or metabolic support of axons by oligodendroglial cells are our 
findings of the coordinated downregulation of the pyruvate dehydrogenase 
kinase 1 (Pdk1) and up-regulation of key metabolic enzymes involved in the 
mitochondrial NADH shuttle, which seems to be required when lactate rather 
than glucose might be available as energy source (Rossner et al., 2006). 
Network analysis formed a cluster of proteins, which are interacting with TP53 
and are deregulated at all time points such as Brain and reproductive organ-
expressed protein (Bre), Reprimo (Rprm), Mediator complex 1 (Med1) and 
Pituitary transforming gene 1 (Pttg1) (Tang et al., 2006; Vanlandingham et al., 
2005; Frade et al., 2000; Bernal et al., 2002). It was recently demonstrated 
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that TP53 not only protects neurons from transformation and DNA damage 
(Jacobs et al., 2006; Helton and X. Chen, 2007) but is also involved in axon 
outgrowth and regeneration (Tedeschi and Di Giovanni, 2009). Med1 
(constitutively higher expressed in CPN of Cnp1 mutants), as one of the most 
significant candidates interacts with nuclear receptors and transcription factors. 
The Mediator coactivator complex, in contrast to chromatin modifying factors, 
acts more directly to facilitate promoter recruitment and function of RNA 
polymerase II and cognate general transcription factors. Another interesting 
candidate, which interacts with TP53 is PTTG1 (Pttg1 is constitutively lower 
expressed in CPN of Cnp1 mutants) since it was found to be down-regulated in 
the wallerian degeneration slow (WldS) mouse model and is presently be 
considered as a candidate for downstream mediation of neuroprotective 
phenotype in Wlds (Gillingwater et al., 2006). Although Pttg1 as well as Med1 
also exhibited the same trend in WM micro-regions and appear therefore not to 
be a neuron specific program but rather a general response of a variety of cell 
to the loss of Cnp1. A third interesting candidate for follow-up investigations is 
cytokeratin 12 (Krt12), which is highly expressed in CPN of WT and Plp1 null 
mutants but absent in Cnp1 null mutants. Krt12 is the unit of a polymeric 
protein complex which forms 10 nm intermediate filaments in epithelial cells 
(Lane, 1993). So far Krt12 has been described as exclusively expressed in 
corneal epithelia and mutations of Krt12 cause Meesmann corneal dystrophy 
(Corden et al., 2000; Sullivan et al., 2007; Seto et al., 2008). In situ data 
derived from Allen-brain-atlas (www.brain-map.org) revealed high signal of 
Krt12 in cortical layer V neurons, which further corroborated our microarray 
data. The function of Krt12 in neurons is so far unknown and will be further 
characterized in a follow up study. 
In summary, we have shown the feasibility to "snapshot" gene expression 
profiles of genetically defined neuronal subtypes in vivo and to compare 
morphologically similar neurons at a given time in pathological conditions. We 
followed gene expression changes starting from early disease states until stages 
of severe pathological signs, focusing on cells known to be susceptible to a 
genetic predisposition. Our analysis revealed several known and novel 
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candidate genes and mechanisms that likely play a role in the early adaptive 
responses of neurons to cope with axonal stress.  
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Appendix A: Genes comprising cluster of Cnp1-/-_Core_Network (CCN) 
 Symbol Description  1M 3M 6M 12M 
Regulation of transcription     
 Med1 mediator complex subunit 1 2,54 3,33 2,41 2,38 
 Hbp1 high mobility group box transcription factor -0,24 -1,05 -1,1 -1,04 
 Id2 inhibitor of DNA binding 2 -0,82 0,17 -0,6 -0,92 
 Mef2c myocyte enhancer factor 2 -1,36 -0,01 -0,15 -0,65 
 Riok2 RIO kinase 2 -0,21 -0,6 -0,47 -0,64 
 Pttg1 pituitary tumor-transforming 1 -4,34 -5,43 -2,63 -4,89 
Cytoskeleton     
 Spnb2 spectrin beta 2 0,03 0,2 0,49 1,32 
 Nefm neurofilament, medium polypeptide -0,48 -0,04 -0,07 -0,67 
 Nefh neurofilament, heavy polypeptide -0,46 -0,06 -0,23 -0,7 
 Mapt microtubule-associated protein tau -0,78 0,02 -0,15 -0,14 
 Lpin1 lipin 1  -0,57 -0,8 0,32 -0,38 
 Krt12 keratin 12 -3,55 -3,81 -3,56 -3,13 
 Dynll2 dynein light chain LC8-type 2 -0,32 -0,37 -0,23 -0,23 
 Kif3a kinesin family member 3A -0,17 -0,56 0,28 -0,66 
 Myl4 myosin, light polypeptide 4 -0,77 -0,5 -0,4 -0,45 
Cholesterol / Lipid     
 Ldlr low density lipoprotein receptor 0,32 0,55 1,65 0,32 
 Npc2 Niemann Pick type C2 0,2 0,38 0,66 0,22 
 Prkab1 protein kinase, AMP-activated, beta 1 non-catalytic subunit 0,46 0,31 1,07 0,01 
 Fabp3 fatty acid binding protein 3, muscle and heart 0,26 0,27 0,17 0,17 
 Apoe apolipoprotein E 0,38 0,5 0,69 1,03 
 Ptgds prostaglandin D2 synthase (brain) 0,55 1,05 1,08 2,18 
 Fasn fatty acid synthase -0,01 0,26 0,56 0,11 
Signaling      
 Rprm reprimo, TP53 dependent G2 arrest mediator candidate -0,07 1,26 0,73 1,19 
 Ubc ubiquitin C -0,49 -0,12 -0,37 -0,35 
 Pdk1 pyruvate dehydrogenase kinase, isoenzyme 1 -0,66 -0,03 0,08 -0,3 
Apoptosis      
 Bre brain and reproductive organ-expressed protein 0,4 0,62 0,88 0,12 
 Ddit4 DNA-damage-inducible transcript 4 -0,09 0,54 0,56 0,72 
 Diablo diablo homolog -0,6 -0,24 -0,4 -1,22 
Others 
 Aldoc aldolase C, fructose-bisphosphate 0,05 0,82 0,38 0,25 
 B2m beta-2 microglobulin 0,22 0,66 0,44 0,54 
 Glul glutamate-ammonia ligase (glutamine synthetase) 0,24 0,12 0,45 0,23 
 Hars histidyl-tRNA synthetase -0,01 1,3 1,15 0,86 
 Hebp1 heme binding protein 1 0,52 0,54 0,32 0,45 
 Hist1h1c histone cluster 1, H1c 0,49 1,24 0,93 0,48 
 Hpca hippocalcin 0 0,83 0,56 0,3 
 Igfbp5 insulin-like growth factor binding protein 5 0,02 0,53 1,42 0,33 
 Igh-6 immunoglobulin heavy chain 6 (heavy chain of IgM) 0,54 1,07 1,81 0,66 
 Mag myelin-associated glycoprotein 0,54 0,46 0,29 0,48 
 Mtx1 metaxin 1 0,16 0,35 0,71 -0,07 
 Ntsr2 neurotensin receptor 2 0,31 0,28 0,93 0,64 
 Rab31 RAB31, member RAS oncogene family 0,14 0,52 0,69 0,73 
 Rpl15 ribosomal protein L15 0,76 0,51 0,6 0,49 
 Rpl3 ribosomal protein L3 0,15 0,27 0,24 0,14 
 Rpl8 ribosomal protein L8 0,13 0,36 0,21 0,14 
 Serpina3n serine (or cysteine) peptidase inhibitor, clade A, member 3N 1,68 1,54 1,62 1,47 
 Sharpin SHANK-associated RH domain interacting protein 0,21 0,57 0,56 -0,13 
APPENDICES 
 
 127
Appendix B: Genes comprising cluster of Cnp1-/-_CPN_3M Network (C3N) 
 Symbol Description  1M 3M 6M 12M 
Transcription     
 Polr2h polymerase (RNA) II (DNA directed) polypeptide H 0,04 0,64 -0,14 -0,53 
 Ddx54 DEAD (Asp-Glu-Ala-Asp) box polypeptide 54 -0,2 0,5 0,55 -0,13 
 Mecp2 methyl CpG binding protein 2 -0,34 0,56 0 -0,07 
 Ndn necdin -0,5 0,71 0,18 -0,2 
 Sf1 splicing factor 1 -0,16 0,53 -0,14 -0,26 
 Sap18 Sin3-associated polypeptide 18 0,02 0,72 0,38 -0,12 
 Lmo4 LIM domain only 4 -0,15 1,21 0,23 -0,27 
 Tcf25 transcription factor 25 (basic helix-loop-helix) -0,06 0,61 0,1 -0,01 
 Sirt3 sirtuin 3  0,03 0,68 -0,12 -0,02 
 Chmp1a chromatin modifying protein 1A -0,02 1,15 0,01 -0,17 
 Elp3 elongation protein 3 homolog (S, cerevisiae) -0,2 0,73 0,42 -0,15 
 Fhl2 four and a half LIM domains 2 -0,31 0,55 0,29 -0,46 
 Foxp1 forkhead box P1 -0,07 0,55 0,6 -0,7 
 Habp4 hyaluronic acid binding protein 4 -0,15 0,66 0,05 -0,09 
 Hdgf hepatoma-derived growth factor 0,1 0,74 0,15 0,16 
 Hey1 hairy/enhancer-of-split related with YRPW motif 1 -0,94 0,3 -0,18 -0,16 
 Lass2 LAG1 homolog, ceramide synthase 2 0,5 0,57 -0,1 0,07 
 Ldoc1l leucine zipper, down-regulated in cancer 1-like -0,16 0,59 0,36 -0,22 
 Lrrc14 leucine rich repeat containing 14 -0,33 0,73 0,19 -0,27 
 Lrrc20 leucine rich repeat containing 20 -0,29 1,12 0,47 0 
 Lrrc59 leucine rich repeat containing 59 0,12 0,77 0,09 -0,12 
 Phb2 prohibitin 2 -0,28 0,85 0,21 -0,08 
 Rnf14 ring finger protein 14 -0,32 0,45 -0,22 -0,38 
 Sqstm1 sequestosome 1 -0,2 0,95 0,3 -0,18 
 Ssbp3 single-stranded DNA binding protein 3 0,11 0,62 0,05 -0,23 
 Tox4 TOX high mobility group box family member 4 -0,16 0,69 -0,14 -0,3 
 Bcl6 B-cell leukemia/lymphoma 6 -0,2 -0,81 -0,77 0,08 
 Ddx5 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 0,05 -0,61 0,02 0,16 
 Hoxc6 homeo box C6 0,31 -0,44 -0,72 0,33 
Cytoskeleton     
 Pak1 p21 (CDKN1A)-activated kinase 1 -0,35 1,27 0,13 -0,09 
 Baiap2 brain-specific angiogenesis inhibitor 1-associated protein 2 -0,06 0,76 -0,22 -0,02 
 Spna2 spectrin alpha 2 -0,19 0,57 -0,15 -0,08 
 Tubb3 tubulin, beta 3 -0,33 0,38 0,01 -0,42 
 Jak1 Janus kinase 1 -0,46 0,85 0,11 0,09 
 Cap2 CAP, adenylate cyclase-associated protein, 2 (yeast) -0,27 0,56 -0,36 -0,31 
 Lasp1 LIM and SH3 protein 1 -0,4 0,68 -0,45 -0,43 
 Maea macrophage erythroblast attacher -0,31 0,5 -0,29 -0,34 
 Sirpa signal-regulatory protein alpha -0,31 0,67 -0,11 -0,26 
 Kalrn kalirin, RhoGEF kinase -0,03 0,45 0,2 -0,03 
 Elmo1 engulfment and cell motility 1, ced-12 homolog (C, elegans) -0,33 0,97 -0,18 -0,22 
 Csrp1 cysteine and glycine-rich protein 1 0,16 1,13 0,51 0,21 
 Capn10 calpain 10 -0,28 0,82 0,22 0,2 
 Cdk2ap1 CDK2 (cyclin-dependent kinase 2)-associated protein 1 -0,11 0,55 0,28 -0,28 
 Elmo2 engulfment and cell motility 2, ced-12 homolog (C, elegans) -0,2 0,65 0,01 -0,22 
 Enc1 ectodermal-neural cortex 1 -0,26 0,25 -0,23 -0,14 
 Epb4,9 erythrocyte protein band 4,9 -0,01 0,89 0,07 -0,04 
Cholesterol / Lipid     
 Fdft1 farnesyl diphosphate farnesyl transferase 1 -0,16 0,57 0,31 0,07 
 Atp5a1 
ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit, 
isoform 1 -0,18 0,96 -0,11 -0,22 
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 Atp5b ATP synthase, H+ transporting mitochondrial F1 complex, beta subunit -0,16 0,64 -0,05 -0,15 
 Got2 glutamate oxaloacetate transaminase 2, mitochondrial -0,53 0,91 0,38 -0,04 
 Cdipt CDP-diacylglycerol--inositol 3-phosphatidyltransferase  -0,1 0,62 -0,08 -0,08 
 Gpsn2 glycoprotein, synaptic 2 -0,32 1,69 0,13 0,18 
 Vamp2 vesicle-associated membrane protein 2 -0,28 0,46 0,09 -0,11 
 Stard3 START domain containing 3 -0,01 0,72 -0,04 -0,08 
 Rab15 RAB15, member RAS oncogene family -0,04 0,87 0,12 0,04 
 Scap SREBF chaperone -0,05 0,61 -0,19 0,11 
 Paqr7 progestin and adipoQ receptor family member VII -0,01 0,63 0,31 -0,34 
 Pitpna phosphatidylinositol transfer protein, alpha -0,08 0,83 -0,13 -0,26 
 Psap prosaposin -0,25 0,98 0,06 0,07 
 Akr1b3 aldo-keto reductase family 1, member B3 (aldose reductase) 0,13 -2,42 -0,07 -0,86 
 Csnk1d casein kinase 1, delta 0,2 -0,27 -0,3 0,56 
Signaling      
 Arrb1 arrestin, beta 1 -0,02 1,02 0,44 -0,12 
 Cacna2d3 calcium channel, voltage-dependent, alpha2/delta subunit 3 -0,42 0,14 0 -0,38 
 Prkcb protein kinase C, beta -0,18 0,59 0,13 0,06 
 Mapk1 mitogen-activated protein kinase 1 -0,44 0,84 0,11 -0,37 
 Map2k1 mitogen-activated protein kinase kinase 1 -0,28 0,91 0,01 0,06 
 Camk2g calcium/calmodulin-dependent protein kinase II gamma -0,04 0,65 0,27 0,06 
 Atp2a2 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 -0,22 0,2 -0,12 -0,13 
 Slc25a5 solute carrier family 25, member 5 -0,23 0,31 -0,22 -0,22 
 Gabrg2 gamma-aminobutyric acid (GABA-A) receptor, subunit gamma 2 -0,53 0,8 -0,2 -0,25 
 Eif4b eukaryotic translation initiation factor 4B -0,19 0,94 0,21 -0,13 
 Aph1a anterior pharynx defective 1a homolog (C, elegans) 0,01 0,92 0,39 -0,04 
 Ngef neuronal guanine nucleotide exchange factor -0,08 1,44 0,39 0,04 
 Asb8 ankyrin repeat and SOCS box-containing 8 -0,47 0,74 0,01 -0,21 
 D0H4S114 DNA segment, human D4S114 0,23 1,37 0,74 -0,21 
 Dclk1 doublecortin-like kinase 1 -0,29 0,61 -0,26 -0,09 
 Gnb5 guanine nucleotide binding protein (G protein), beta 5 0,06 0,54 -0,36 -0,13 
 Slc2a1 solute carrier family 2 (facilitated glucose transporter), member 1 0,1 -0,91 -0,39 0,41 
 Ptpn2 protein tyrosine phosphatase, non-receptor type 2 0,36 -1,01 0,48 -0,1 
 Pdcd5 programmed cell death 5 0,19 -0,57 -0,06 0,09 
Apoptosis      
 App amyloid beta (A4) precursor protein 0,04 1,19 -0,18 -0,05 
 Vdac1 voltage-dependent anion channel 1 -0,25 0,57 -0,08 -0,31 
 Ube2z ubiquitin-conjugating enzyme E2Z (putative) 0,09 0,58 -0,39 0,01 
 Prkar1b protein kinase, cAMP dependent regulatory, type I beta -0,06 1,34 0,16 0,05 
 Prdx2 peroxiredoxin 2 0,16 0,58 -0,08 -0,38 
 Bcl2l2 BCL2-like 2 -0,18 0,79 0,35 0,15 
 Fem1b feminization 1 homolog b (C, elegans) -0,27 0,59 -0,33 -0,29 
 Rnf34 ring finger protein 34 -0,04 0,54 -0,33 -0,21 
 Tegt testis enhanced gene transcript 0,06 0,36 -0,14 0,28 
 Pgam1 phosphoglycerate mutase 1 -0,18 0,55 -0,11 -0,14 
 Thoc1 THO complex 1 0,34 -1,12 0,25 -0,3 
 Akr1b3 aldo-keto reductase family 1, member B3 (aldose reductase) 0,27 -2,55 -0,18 -1,05 
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Appendix C: Genes comprising cluster of Cnp1-/-_CPN_6M Network (C6N) 
 Symbol Description  1M 3M 6M 12M 
Transcription     
 Gtf2h2 general transcription factor II H, polypeptide 2 -0,02 0,42 0,64 -0,87 
 Jun Jun oncogene 0,07 0,22 1,22 0,97 
 Nr3c1 nuclear receptor subfamily 3, group C, member 1 -0,42 0,46 0,38 -0,3 
 Mitf microphthalmia-associated transcription factor -0,35 -0,27 2,06 -0,29 
 Med8 mediator of RNA polymerase II transcription, subunit 8 homolog (yeast) -0,2 0,5 1,03 -0,45 
 Tcf12 transcription factor 12 0,08 0 1,37 -0,22 
 Med22 mediator complex subunit 22 0,21 0,59 0,3 -0,31 
 Xab2 XPA binding protein 2 0,15 -0,5 0,56 0,28 
 Hmgb3 high mobility group box 3 0 1,11 1,17 -0,36 
 Mbtps1 membrane-bound transcription factor peptidase, site 1 -0,2 0,5 0,59 -0,24 
 Mll1 myeloid/lymphoid or mixed-lineage leukemia 1 -0,11 -0,21 0,75 0,24 
 Pqbp1 polyglutamine binding protein 1 0,12 -0,19 0,51 0,09 
 Purb purine rich element binding protein B 0,23 -0,58 0,99 -0,6 
 Rcor1 REST corepressor 1 -0,32 -0,17 0,45 -0,71 
 Gtf2e2 general transcription factor II E, polypeptide 2 (beta subunit) -0,4 0,12 -1,26 -0,52 
 Nfatc2 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 -0,05 0,11 -1,05 0,23 
 Med1 (short) mediator complex subunit 1 -0,3 -0,11 -0,74 -0,62 
 Bzw1 basic leucine zipper and W2 domains 1 -0,11 -0,06 -0,55 -0,65 
 Dmtf1 cyclin D binding myb-like transcription factor 1 -0,32 0,23 -1,25 -0,85 
 Klf10 Kruppel-like factor 10 0,03 -0,2 -0,98 -0,46 
 Tsc22d3 TSC22 domain family, member 3 -0,28 -0,12 -0,4 -0,77 
 Sfpq splicing factor proline/glutamine rich  -0,56 0,09 -1,16 -0,52 
Cytoskeleton     
 Cfl2 cofilin 2, muscle -0,58 0,08 1,1 -0,76 
 Fhod3 formin homology 2 domain containing 3 -0,18 0,45 0,5 -0,22 
 Rock2 Rho-associated coiled-coil containing protein kinase 2 -0,11 -0,27 -1,1 -0,81 
Cholesterol / Lipid     
 Nsdhl NAD(P) dependent steroid dehydrogenase-like -0,03 0,68 0,76 -0,08 
 Tm7sf2 transmembrane 7 superfamily member 2 0,11 0,51 0,97 -0,22 
 Hexb hexosaminidase B 0,5 -0,74 0,54 0,65 
 Dbi diazepam binding inhibitor -0,11 -0,07 0,75 0,24 
 Scp2 sterol carrier protein 2, liver -0,07 0,46 0,34 -0,2 
 0610007P14Rik RIKEN cDNA 0610007P14 gene 0,15 0,51 0,52 -0,37 
 Asah2 N-acylsphingosine amidohydrolase 2 -0,04 -0,37 0,43 -0,21 
 Erlin1 ER lipid raft associated 1 0,02 -0,22 0,99 -0,18 
 Hsd17b11 hydroxysteroid (17-beta) dehydrogenase 11 -0,11 -0,02 0,71 0,29 
 Pgrmc2 progesterone receptor membrane component 2 -0,1 0,25 0,5 -0,15 
 Sqle squalene epoxidase 0,09 0,41 1,03 -0,22 
 Prkag2 protein kinase, AMP-activated, gamma 2 non-catalytic subunit 1,14 0,28 -0,43 -0,85 
 Rgs19 regulator of G-protein signaling 19 0,25 0,04 -0,79 -0,4 
Signaling      
 Dbi diazepam binding inhibitor 0,12 -0,34 0,5 0,39 
 Dusp8 dual specificity phosphatase 8 -0,1 0,03 0,68 0,21 
 Map4k4 mitogen-activated protein kinase kinase kinase kinase 4 0,11 -0,11 0,77 -0,28 
 Phka2 phosphorylase kinase alpha 2 0,07 -0,45 1,2 0,2 
 Ifnar2 interferon (alpha and beta) receptor 2 -0,13 0,33 0,85 -0,51 
 Npy neuropeptide Y 1 -1,12 1,62 1,15 
 Sel1l sel-1 suppressor of lin-12-like (C, elegans) -0,16 0,02 0,61 -0,43 
 Il11ra1 interleukin 11 receptor, alpha chain 1 0,11 0,29 -0,33 -0,81 
 Rfwd2 ring finger and WD repeat domain 2 -0,41 0,05 -0,39 -0,28 
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 Adcyap1 adenylate cyclase activating polypeptide 1 -0,35 0,22 -0,94 -0,59 
 Adam19 a disintegrin and metallopeptidase domain 19 (meltrin beta) 0,09 -0,13 -1,27 -0,49 
Apoptosis      
 Syvn1 synovial apoptosis inhibitor 1, synoviolin -0,09 0,59 0,57 -0,15 
 Cdc2l1 cell division cycle 2-like 1 0,39 0,3 0,32 -0,2 
 Acat2 acetyl-Coenzyme A acetyltransferase 2 0,21 -0,21 0,56 0,64 
 Polb polymerase (DNA directed), beta -0,06 -0,14 -1,01 -0,29 
 Bdnf brain derived neurotrophic factor -0,03 -0,51 -1,2 -0,81 
 Pdcd2 programmed cell death 2 -0,22 -0,11 -0,61 -0,55 
 Cs citrate synthase -0,3 -0,17 -0,69 0,01 
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Appendix G: Abbreviations 
°C Degrees Celsius (centigrades) 
µg Microgram 
µl Microliter 
µm Micrometer 
Amg Amygdala 
AONDs Adult-onset neurodegenerative diseases 
APC Adenomatous polyposis coli 
APP Amyloid precursor protein 
APS Ammonium persulfate 
AS Astrocytes 
BP Biological process 
bp Base pairs 
Bre Brain and reproductive organ-expressed protein 
BSA Bovine serum albumin 
C3ar1 Complement component 3a receptor 1 
CC Cellular component 
Ccl3 Chemokine (C-C motif) ligand 3 
CCN Cnp1-/-_Core_Network 
C3N Cnp1-/-_3M_Network 
C6N Cnp1-/-_6M_Network 
Chrna3 Cholinergic receptor, nicotinic, alpha polypeptide 3 
Chrna5 Cholinergic receptor, nicotinic, alpha polypeptide 5 
CNP / Cnp1 2’, 3’-cyclic nucleotide 3’-phosphodiesterase 
CNS Central nervous system 
CPN Callosal projection neurons 
Csf1r Colony stimulating factor 1 receptor 
Cspg4 Chondroitin sulfate proteoglycan 4 
Cx Cortex 
DAB 3,3'- Diaminobenzidine 
Dcx Doublecortin 
ddH2O Double distilled (or miliQ) water 
DMSO Dimethylsulfoxide 
EB I Elution buffer I 
EB II Elution buffer II 
EDTA Ethylened acid 
EGFP Enhanced green fluorescent protein 
Egfr Epidermal growth factor receptor 
Eno2 Enolase 2 
Enpp2 Extracellular lysophospholipase D 
EYFP Enhanced yellow fluorescent protein 
EYFPnuc Nuclear-targeted EYFP 
f.c. Final concentration 
FACS Fluorescent-activated cell sorting 
FC Fold change 
gcos Gene chip operating software 
GO Gene Ontology 
GPC Glial precursors cells 
Grin1 Glutamate receptor, ionotropic, NMDA1 
GSEA Gene set enrichment analysis 
HE Haematoxylin-Eosin 
HE Haematoxylin-Eosin staining 
hGFAP Human glial fibrillary acidic protein 
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HS Horse serum 
Iba1 Ionized Ca2+-binding adaptor 1 
IHC Immunohistochemstry 
IP Immunoprecipitation 
ISH in-situ hybridization 
Kb Kilobases 
kDa Kilodalton 
ko Knock-out (null mutant) 
Krt12 Cytokeratin 12 
LB Luria-Bertani broth 
LCM Laser capture microdissection 
LV Lateral ventricle 
M Molar 
mA MilliAmpere 
Mal Myelin and lymphocyte protein 
Med1 Mediator complex 1 ( 
MF Molecular function 
MG Microglia 
MGB Modified Gitschier buffer 
min Minutes 
ml Milliliter 
mM Millimolar 
mo Month 
Mobp Myelin-associated oligodendrocyte basic protein 
Mog Myelin oligodendrocyte glycoprotein 
MS Multiple Sclerosis 
MSigDB Molecular Signature Database 
Myo10 Myosin 10 
NB Neutralization buffer 
Ncam1 Neural cell adhesion molecule 1 
Nefm Neurofilament, medium polypeptide 
ng Nanogram 
nm Nanometer 
Npas1 Neural PAS domain protein 1 
OL Oligodendrocytes 
ON Overnight 
OPC Oligodendrocyte progenitor cell 
P Postnatal day 
PABP Poly(A)-binding protein 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
PC Purkinje cells 
PCA Principal component analysis 
PCR Polymerase chain reaction 
Pdgfra Platelet derived growth factor receptor, alpha 
Pdk1 Pyruvate dehydrogenase kinase 1 
PFA Paraformaldehyde 
Pfkm Phosphofructokinase-1 
PI Propidium iodide 
Plat Plasminogen activator, tissue 
PLP /Plp1 Proteolipid protein 
PMD Pelizaeus-Merzbacher disease 
PMSF Phenylmethanesulphon 
PNS Peripheral nervous system 
Polr3h Polymerase (RNA) III (DNA directed) polypeptide H 
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Ptgds2 Prostaglandin D2 synthase 2, 
Pttg1 Pituitary transforming gene 1 
QC Quality control 
QRT-PCR Quantitative real-time PCR 
RMA Robust Multichip Average 
Rprm Reprimo 
RQ Relative qunatity 
RT Room temperature 
SC Schwann cell 
SD Standard deviation 
SDS Sodium dodecyl sulfate 
sec Seconds 
SEM Standard error mean 
Sir2 Sirtuin-2 
SN Substantia nigra 
SNR Signal-to-Noise ratio 
Sox10 SRY-box containing gene 10 
SPG2 Spastic paraplegia 2 
ssDNA Single stranded DNA 
TBE Tris-Borat-EDTA 
TBS Tris buffered salin 
TBST TBS with Tween 
TH Tyrosine hydroxylase 
Thy1 Thymus cell antigen 1 
Tnc Tenascin-C 
Tris-HCl Tris-(hydroxymethyl)-amin 
Ttll1 Tubulin tyrosine ligase-like 1 
U Unit, (for enzyme activities) 
V Volt 
VTA Ventral tegmental area 
WB Western blotting 
WB I Wash buffer I 
WB II Wash buffer II 
WldS Wallerian degeneration slow 
WM White matter 
WT Whole transcript 
wt Wildtype (control) 
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Scientific education: 
1998 – 2000 Basic studies in Biology, Friedrich-Alexander-University 
Erlangen 
2000 – 2004 Advance studies in Biology, Ruprecht-Karls- University 
Heidelberg  
Degree: Diploma 
Main focus: Molecular Biology, Biochemistry,  Cellbiology 
May 2005 - present  Dissertation at Max Planck Institute for experimental 
Medicine, Göttingen  
APPENDICES 
 138
 Department Neurogenetics  
 Subject: “Transcriptomic approaches in the brain 
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Language 
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Spanish - basic 
Courses and Stipends 
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